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Summary 
Acute lymphoblastic Leukemia (ALL) is a disease of the bone marrow and the blood, which 
represents the most recurrent cancer in childhood. ALL can be cured with multimodal 
chemotherapy in approximately 80% of the cases. Short and long term toxicity can be 
significant. Nevertheless a substantial number of patients with ALL will eventually relapse 
by acquiring treatment resistance. Therefore this disease is still one of the leading causes of 
death in children. On current treatment protocols of the BFM study group (one of the largest 
cooperative study groups for the treatment of ALL, still named Berlin-Frankfurt-Muenster 
(BFM), to credit the important contribution of the founding centers) for childhood ALL, a 
group of patients with exceedingly poor prognosis can be identified based on the persistence 
of minimal residual disease. Most of these very high risk patients (VHR-ALL) are also 
resistant to glucocorticoids (GC) and will qualify for experimental therapy upfront. A general 
model in the field proposes the blockade of the intrinsic apoptotic pathway as a mechanism of 
GC resistance. Gene expression profiling studies strongly suggest that GC-resistance is 
associated with upregulation of metabolic signatures (glycolysis, oxidative phosphorylation, 
cholesterol biosynthesis and glutamate metabolism) and activation of PI3K/AKT/mTOR 
pathways [1]. Consistent with these data, we demonstrated that interference with AKT 
signaling using arsenic trioxide can restore sensitivity to glucocorticoids in ALL cells from 
prednisone poor responders patients (publication1) [2]. This work identified members of the 
pro-survival PI3K/AKT pathway as rational targets for therapeutic intervention in this 
subgroup of high risk ALL. Armstrong et al [1] proposed based on gene expression profiling, 
that overexpression of the anti-apoptotic protein MCL-1 is associated with resistance to 
glucocorticoids in ALL. We therefore decided to evaluate the new compound obatoclax, a 
pan-BCL-2 inhibitor selected based on its capability to bind and antagonize MCL-1, to act as 
a chemosensitizer. Using a xenograft model in immunodeficient mice, we could demonstrate 
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that obatoclax conveys a strong and broad chemosensitization effect in primary ALL cells 
from patients with highly resistant disease (publication 2) [3]. Unexpectedly, re-sensitization 
to glucocorticoids resulted from activation of an alternative cell death pathway to bypass the 
apoptotic blockade in GC resistant cells. This effect was dependent on rapid and specific 
induction of autophagy, as demonstrated in rescue experiments using pharmacologic 
inhibitors of autophagy or specific knock-down of autophagy genes. However, execution of 
cell death was also dependent on RIP-1 kinase activity, which we show to act downstream of 
autophagy. Furthermore, combination of obatoclax and dexamethasone resulted in 
characteristic cell death morphology by electron microscopy that is reminiscent of induction 
of a necrotic cell death pathway [4], also referred to as necroptosis [5-6]. Importantly, in 
combination with other non-glucocorticoid antileukemic agents, obatoclax also conveyed 
very effective chemosensitization, but this effect was associated with induction of 
mitochondrial apoptosis. The specific induction of autophagy dependent necroptosis in 
combination with dexamethasone was associated with two events that could contribute to the 
cell death trigger mechanism. First, low concentrations of obatoclax were sufficient to disrupt 
the interaction between the autophagy regulator Beclin-1 with the anti-apoptotic regulator 
MCL-1 which may interfere with repression of autophagy by this BCL-2 family member. 
Second, only in combination with dexamethasone, obatoclax resulted in strong inhibition of 
mTOR kinase activity, which is known to modulate induction of autophagy. Finally, we 
could show strong preclinical in vivo activity for this approach, using a xenograft model with 
relevant patient samples. Taken together, this work provides compelling evidence to support 
a rapid translation of this approach to the clinics. Accordingly, a phase-I clinical trial is in 
final preparation in collaboration with major European Institutions. Our data provide the 
basis for the evaluation of the biological response to the combination of obatoclax and 
dexamethasone in patients with refractory ALL and have been critical to obtain first priority 
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for this clinical study in Europe. From a mechanistic standpoint, our data provide a unique 
experimental system to investigate the molecular events that link autophagy, necroptosis and 
apoptosis in a clinically highly relevant setting. Finally, our experimental platform can be 
expanded for high content screens, which will open new avenues for the investigation of drug 
resistance in ALL and the triage of the most effective therapeutic agents for highly resistant 
disease.  
Zusammenfassung 
4
Zusammenfassung 
Akute lymphoblastische Leukämie (ALL) ist eine Krankheit des Knochenmarkes und Blutes 
und ist die häufigste Krebsart bei Kindern. ALL kann mit multimodaler Chemotherapie in 
zirka 80% aller Fälle geheilt werden, wobei aber Kurzzeit- und Langzeittoxizität signifikant 
sein können. Leider gelingt es nicht, die restlichen 20% zu heilen, da sie auf die 
Chemotherapie resistent sind. Deshalb ist die ALL immer noch eines der grössten Probleme 
in der Pädiatrie. Derzeitige Behandlungsprotokolle der BFM-Studiengruppe (eine der 
grössten kooperativen Studiengruppen für die Behandlung von ALL, benannt nach den 
Gründungszentren Berlin-Frankfurt-Münster) identifizieren basierend auf anhaltender 
minimaler Resterkrankung (MRD) eine Patientengruppe mit ausgesprochen schlechter 
Prognose. Die meisten dieser Hochrisikopatienten (VHR-ALL) sind auch auf 
Glukokortikoide (GC) resistent und qualifizieren für experimentelle Therapie. Als gängiges 
Modell für den Mechanismus der GC-Resistenz wird die Blockade des intrinsischen 
apoptotischen Pfades gehandelt. Genexpressionsprofile deuten daraufhin, dass die GC-
Resistenz mit der Hochregulation von metabolischen Signaturen (Glykolyse, oxidative 
Phosphorylierung, Cholesterinbiosynthese und Glutamatmetabolismus) und der Aktivierung 
des PI3K-AKT-mTOR Signalweges zusammenhängt [1]. In Übereinstimmung mit diesen 
Daten haben wir gezeigt, dass durch die Inhibition des AKT-Signalweges mit Arsentrioxid 
Patienten mit GC-Resistenz resensitisiert werden (Publikation 1) [2]. In der Untergruppe der 
Hochrisikopatienten identifiziert diese Arbeit Mitglieder des PI3K-AKT Signalweges als 
therapeutische Zielproteine. Armstronget al. [1] schlugen aufgrund von 
Genexpressionsprofilen vor, dass die Überexpression des anti-apoptotischen Proteins MCL-1 
mit der GC-Resistenz in der ALL zusammenhängt. Daher haben wir uns entschlossen, den 
neuen Wirkstoff Obatoclax, einen pan-BCL-2-Inhibitor, zu evaluieren. Dieser Inhibitor 
wurde mit der Hoffnung selektionert, aufgrund seiner MCL-1 antagonisieren der Eigenschaft 
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glukokortikoid-resistente ALL Zellen auf ebendiese Glukokortikoide wieder empfindlich zu 
machen. Mit Hilfe unseres Xenograft Modells mit immundefizienten Mäusen konnten wir 
zeigen, dass Obatoclax einen starken und breitbandigen Chemosensitisierungseffekt in 
primären ALL-Zellen von VHR-ALL-Patienten hat (Publikation 2) [3]. Unerwarteterweise 
erfolgte die Resensitisierung auf Glukokortikoide durch die Aktivierung eines alternativen 
Zelltodweges und umging die Blockade der Apoptose in GC-resistenten Zellen. Dieser Effekt 
war abhängig von der schnellen und spezifischen Induktion der Autophagie und wurde durch 
pharmakologische Inhibition der Autophagie oder spezifische Inaktivierung von 
Autophagiegenen mittels RNA Interferenz aufgehoben. Zudem war die Ausführung des 
Zelltodes auch abhängig von der Aktivität der RIP-1 Kinase, welche dem Autophagie-
Signalweg nachgeschaltet ist. Darüber hinaus zeigten elektronenmikroskopische Aufnahmen, 
dass Zellen nach der Behandlung mit der Kombination von Obatoclax und dem 
Glukokortikoid Dexamethason eine charakteristische Morphologie des Zelltodes aufweisen, 
welche der Nekrose ähnlich ist [4] und auch Nekroptose genannt wird [5-6]. Es ist wichtig zu 
erwähnen, dass Obatoclax resistente Zellen auch auf andere, nicht-glukokortikoidale 
antileukämische Medikamente empfindlich gemacht hat. Dieser Effekt war aber abhängig 
von der mitochondrialen Apoptose. Wir haben zwei Mechanismen identifiziert, die für die 
Induktion der autophagie-abhängigen Nekroptose im Beisein von Dexamethason 
verantwortlich sein können. Erstens genügten niedrige Konzentrationen von Obatoclax, um 
die Interaktion zwischen dem Autophagieregulator Beclin-1 mit dem antiapoptotischen 
Regulator MCL-1 zu stören, welches die Blockade der Autophagie aufheben könnte. 
Zweitens führte Obatoclax in Kombination mit Dexamethason zu einer starken Inhibition der 
Aktivität der Kinase mTOR, welche die Induktion der Autophagie reguliert. Mit dieser 
Kombinationstherapie konnten wir schliesslich in unserem Xenograft-Modell überzeugende 
präklinische Daten erzeugen, die eine sehr hohe therapeutische Effektivität auf relevante 
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Patientenproben zeigen. Diese Arbeit bietet eine solide Grundlage, um eine schnelle 
Umsetzung in die klinische Anwendung zu erreichen. So ist eine klinische Phase-I Studie in 
Zusammenarbeit mit den wichtigsten europäischen Instituten in Vorbereitung. Unsere Daten 
schaffen die Basis für die Evaluierung der biologischen Antwort auf die 
Kombinationsbehandlung mit Obatoclax und Dexamethason in Patienten mit refraktärer ALL 
und haben entscheidend dazu beigetragen, um dieser klinischen Studie die höchste Priorität in 
Europa zu gewähren. Wir haben gleichzeitig ein einzigartiges experimentelles System 
geschaffen, um in einem klinisch hochrelevanten Hintergrund von einem mechanistischen 
Standpunkt aus die molekularen Ereignisse zu untersuchen, die Autophagie, Nekroptose und 
Apoptose verbinden. Dieses System kann jetzt ausgebaut werden, um in hochauflösenden 
Untersuchungen neue Ansätze zur Behandlung von therapie-refraktären Leukämien zu 
evaluieren und die besten Kandidaten für weitere klinische Studien herauszutriagieren. 
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Introduction 
Chapter 1: Childhood acute lymphoblastic leukemia 
Childhood acute lymphoblastic leukemia is the most frequent cancer in childhood. Despite 
cure rates among children with ALL of 80%, the current therapies have substantial toxic 
effects and relapse remains a significant problem [7-11]. Leukemia relapse constitutes the 
fourth most frequent diagnosis in pediatric Oncology in the US and the fifth most frequent 
diagnosis in the Swiss Childhood Cancer Registry, which underscores the need for new 
treatment modalities. Leukemia can arise in the B-cell and T-cell lineages and is 
characterized by abnormal proliferation and a predominance of immature blast cells, blocked 
in an early differentiation stage (Figure 1) in blood and bone marrow.  
             
Figure 1: B-cell differentiation stages adapted from [12]. 
Diagnosis and treatment of childhood ALL depend on the unequivocal detection of a 
leukemic cell population and identification of the hematopoietic lineage (which includes CD 
markers and Ig or TCR genes rearrangement) from which the population originates [13-14] 
(Table 1). Immunoglobulin (Ig) and T cell receptor (TCR) gene rearrangements occur during 
normal lymphoid development and represent a fingerprint for each individual cell and its 
progeny. Thus, they are widely used as clone-specific markers for clonality analysis of 
lymphoid cells. They are present in virtually all lymphoid leukemias and may exert specific 
features as a consequence of the i) age of the patients and/or ii) leukemia subgroup, even 
though they are not causally linked to the leukemia development. Furthermore, the leukemia 
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clone-specific Ig/TCR rearrangements may provide information about the time at which the 
target cell of the leukemia is transformed as well as to the differentiation stage of the 
precursor cell. Clonal Ig or TCR rearrangements provide essential markers to follow 
treatment response by Q-PCR to measure minimal residual disease (MRD). 
Sub-type                            Leukemic antigen expression (% of positive cases) 
 CD19 cCD22 CD10 CD7 CD5 cCD3 cIg µ sIg µ sIgκ/λ
Early pre-B 100 > 95 95 5 0 0 0 0 0 
Pre-B 100 100 >95 0 <2 0 100 100 0 
Late pre-B 100 100 50 0 0 0 100 100 0 
B-ALL 100 100 50 0 0 0 >95 >95 >95 
T-ALL <5 0 45 100 100 100 0 0 0 
Table 1: Immunophenotypes of acute lymphoblastic leukemias adapted from [15]. 
Acute lymphoblastic leukemia is a complex disease. In the past, discovery of genetic factors 
contributing to the pathogenesis of ALL were limited by the low resolution of conventional 
cytogenetic analysis and to molecular analysis of selected individual genes. The analysis of 
recurrent genetic abnormalities identified a number of important genes that are implicated in 
the pathogenesis of the disease. Important insights came from twin analysis and detection of 
lesions that are characteristic for leukemia in neonatal cord blood, even before emergence of 
the disease [16-19]. This type of analysis strongly suggests the existence of preleukemic 
clones with primary genetic lesions, which will evolve to full blown disease with additional 
lesions [20]. A fascinating Darwinian evolutionary model has recently been proposed by 
Greaves [21]. This model suggests that the first "hit" or first mutation happens prenatally and 
occurs very commonly, indicating a low penetrance or low evolutionary progression. The 
acquisition of the critical, secondary CNAs requires some Darwinian selective advantage to 
expand numbers of cells at risk, like for example TGF beta. The clonal architecture of ALL 
has been investigated by single cell analysis with multicolor probes to mutant genes. The data 
do not reveal a linear sequence of mutation acquisition with clonal succession but rather 
considerable complexity with a tree-like or branching structure of genetically distinct 
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subclones very reminiscent of Darwin’s divergence evolutionary diagram. This pattern has 
important implications for stem cells in ALL, for the origins of relapse and for therapeutic 
targeting. With the rapid progress using novel high throughput genomic technologies, a 
picture of the genetic complexity of ALL is emerging. Genome wide transcriptome analyses 
have permitted molecular classification of the disease and led to the identification of relevant 
gene expression signatures characteristic for different subgroups, which can be exploited as 
discovery tools for hypothesis generation [22-24]. The limitation of gene expression profiling 
is the difficulty in identifying critical genetic lesions from the long list of deregulated genes 
characteristic of each cancer or leukemia subtype. In contrast, significant progress is expected 
from new genetic approaches. Several groups reported studies using high resolution single 
nucleotide polymorphism (SNP) arrays of diagnostic leukemic samples, which suggest the 
coexistence of several recurrent genetic aberrations in ALL, mostly small deletions of critical 
genetic material, but often also chromosomal translocations leading to an oncogenic fusion 
genes and in some instance seven specific gain of genes. Through the systematic use of SNP 
arrays we begin to understand which cellular pathways may be targeted by DNA copy 
number alterations (CNAs). In a majority of cases, master regulators of lymphoid 
development are deleted, including PAX5, EBF and IKZF1 [25]. Other critical targets appear 
to include regulators of the cell cycle, tumor suppressor genes (PTEN, BF1, RB1) and 
regulators of apoptosis (BTG1). Loss of genes regulating B-lymphoid development is present 
in 60% of pro-B ALL, and this accelerates leukemogenesis in experimental models [23, 25-
26], suggesting that these alterations contribute to the process of leukemogenesis in human 
ALL. Mullighan et al [27] underlined the fact that the average number of CNA in leukemia 
was generally restricted to a limited number of alterations, about six per cases indicating that 
in general, ALL is not characterized by gross genomic instability. Furthermore there were 
significant differences in the number of CNA among ALL. For example, MLL-rearranged 
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ALL cases had less than one CNA per case, suggesting that few cooperating aberrations are 
necessary to induce leukemogenesis. In contrast, BCR-ABL positive leukemia harbored over 
six aberrations per case, suggesting the requirement for multiple additional lesions for 
leukemogenesis. In this last group, one of the most recurrent lesions was found in the IKZF1 
gene [25]. Deletion of IKZF1, which encodes the transcription factor Ikaros, was detected in 
83.7% of BCR–ABL1 ALL cases, including 76.2% of pediatric and 90.9% of adult BCR–
ABL1 ALL cases (Figure 2). Deletion of PAX5 occurred in 51% of BCR–ABL ALL cases, 
with the majority also having a deletion of IKZF1 (95%). This suggests that deletion of 
IKZF1 is associated with a very poor outcome in B-cell-progenitor ALL and could contribute 
to resistance to chemotherapy.  
                          
Figure 2: BCR-ABL positive ALL is characterized by the deletion of Ikaros [25]
An integrated approach combining high throughput genomic techniques, deep sequencing of 
the leukemia genome, and epigenetic profiling (e.g methylation arrays to detect modification 
in promoter and enhancer regions of candidate genes), will lead to the identification of new 
lesions in ALL. But linking these data to biological function and clinical significance will 
require datasets that enable conclusive correlations with clinical outcome data and 
experimental platforms for functional investigation of the different lesions 
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Prognostic factors 
Several clinical and biologic features have been found to have important prognostic 
significance in childhood ALL (Table 2), including age, leukocyte count at presentation, 
immunophenotype, recurrent chromosomal abnormalities, and response to initial therapy [7]. 
These prognostic factors have been used to stratify patients for optimal therapy  adaptation; 
patients with ‘high risk’ features have received more intensive treatments, whereas some of 
the more intensive components of therapy have been modified or eliminated for those 
children with more favorable presenting features. 
Prognostic Factors 
Favorable 
    Hyperdiploidy with trisomies of chromosomes 4, 10, 17 
    TEL/AML1 fusion-positive 
     Low end-induction (day 29) MRD (_0.01%) 
     Low end-induction (day 29) MRD with either double trisonomies (4,10) or 
     TEL/AML1 fusion 
Unfavourable 
      Hypoploidy ( less than 45 chromosomes) 
      Intrachromosomal AML1 amplification 
      MLL-rearranged 
      High end-induction (day 29) MRD (>0.01%) 
      Philadelphia Chromosome positive cells 
      Ikaros deletion 
Table 2: Recently reported prognostically distinctive subsets of children with B-precursor acute lymphoblastic leukemia
Despite the rapid gain of knowledge about recurrent genetic lesions in ALL, so far only a 
very limited number of these alternations can serve as predictive markers for risk 
stratification in ALL treatment [28]. For instance, the chromosomal translocation t(9;22) 
resulting in the BCR-ABL fusion gene, an activated oncogenic kinase, is associated with 
worse outcome. However, more recent studies in this subgroup demonstrate that assessment 
of in vivo response to treatment using molecular methods still enables to discriminate among 
poor and good responders within this subgroup (A. Biondi, AEIOP-BFM study group, 
personal communication). On the other hand, the translocation t(11;21) leading to the fusion 
gene ETV6-RUNX1 (TEL-AML1) is clearly associated with favorable prognosis but rare 
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occurrence of late relapses [29]. It is likely that the new generation of genomic studies will 
identify additional useful prognostic markers, which would be very valuable to assign 
patients at risk to experimental therapy early during their first line treatment.  
However, so far, assessment of the response to treatment in vivo, by measuring minimal 
residual disease (MRD) using qPCR after different blocs of chemotherapy remains by far the 
most powerful approach for patient stratification in ALL [30-31]. To detect MRD junctional 
regions of Ig or TCR gene rearrangements are suitable PCR targets, because they contain 
unique sequences owing to the deletion and random insertion of nucleotides during the 
rearrangement process. Cases with no detectable MRD at 5 weeks and 12 weeks (measured 
by qPCR) after diagnosis are classified as standard-risk, and those with high levels of MRD 
(more than 10-3) detectable at both time points, together with patients who have the Ph 
chromosome, the t(4;11) or initial induction failure, are considered as high-risk of relapse. All 
the others are considered to have medium-risk leukemia. HR patients can be further 
subdivided based on persistence of residual disease during consolidation therapy. This group 
of patients can be considered as very high risk of relapse (VHR) (Figure 3). About half of 
these patients are steroid resistant. 
Figure 3: In vivo response to treatment: monitoring of minimal residual disease (MRD)  
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Of relevance for our work, a poor response to glucocorticoids, as evidenced by persistence of 
leukemic cells after a window of one week monotherapy with the glucocorticoid (GC) 
prednisone is a strong independent predictor of poor outcome in childhood ALL [32].
However in most if not all cases, patients with very resistant or refractory disease will have a 
poor MRD response in vivo which correlates with resistance to multiple chemotherapeutic 
agents in vitro, as evidenced by our study (Publication 2) [3]. The importance of 
glucocorticoids for the control of the disease is also reflected by the fact that a significant 
proportion of patients with refractory disease are also resistant to glucocorticoids   
Molecular mechanism of glucocorticoid action 
GCs constitute an essential component of the treatment of lymphoid malignancies, including 
childhood acute lymphoblastic leukemia [12] due to their ability to induce apoptosis in 
lymphoid cells [33]. The mechanism of action in ALL is still controversial. The GC-induced
apoptotic response is thought to be mediated through the glucocorticoid receptor (GR), a 
member of the nuclear receptor family of ligand-dependent  transcription factors, which is 
localized in the cytoplasm of unstimulated cells [34]. Ligand binding to the GR results in its 
dissociation from chaperone proteins that tether the receptor in the cytoplasm, causing a 
conformational change in the protein that allows nuclear translocation, receptor dimerization, 
DNA binding, and transactivation [35]. The activated receptor-ligand complex translocates to 
the nucleus where it binds as a homodimer to specific GC-response elements (GRE) found in 
the promoter and enhancer regions of GC-responsive genes (Figure 4). 
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Figure 4: Glucocorticoids: mechanism of action   
In lymphoblasts changes in gene expression caused by receptor activation ultimately result in 
induction of apoptosis [36-37]. GC receptor induced transactivation of GRE containing genes 
and transrepression of genes via NF-κB and AP-1 interactions are thought to be essential [38-
39]. GC induced cell death was shown to occur through the mitochondrial apoptotic pathway 
and depends on protein synthesis and de novo of target genes [40-41]. Brady et al. showed 
that the effect of GCs is p53 independent [42]. 
Despite the central role of glucocorticoids in all protocols for the treatment of ALL, the 
mechanisms by which they act on their target cells, and lesions underlying GC resistance,
remain poorly understood [35]. This is due, in part, to lack of suitable experimental systems to 
study the disease. Due to the limited proliferate capacity of primary leukemia cells in vitro, 
studies investigating GC-resistance have focused to a large extent on laboratory-derived ALL 
cell lines. Resistance in such cell lines is almost invariably associated with defects in 
receptor-ligand interactions, such as mutations in the ligand binding domain of the GR [33, 
37, 43]. However, similar studies using primary patient samples have detected only isolated 
cases with somatic mutations in the GR, leading to poor GC-response [44-46]. Although 
existing data are conflicting, the majority of studies have failed to associate GC-resistance in 
patient samples with either relative expression of the various isoforms of the receptor [46-47], 
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polymorphisms within the coding region of the GR gene or expression levels of co-chaperone 
proteins associated with the GR [48]. 
Molecular mechanism of steroid resistance in childhood ALL 
Resistance to glucocorticoids in ALL was proposed to be associated to defect in the apoptotic 
machinery. Indeed, our work and studies by others [38, 49] have demonstrated that the 
apoptotic response to glucocorticoids is blocked in steroid resistance. Because several groups 
reported an increase of mRNA levels of the anti-apoptotic regulator MCL-1 in GC-resistant 
ALL and based on the observation the upregulation of the pro-apoptotic BCL-2 family 
protein BIM was altered in GC-resistant ALL, deregulation of the control of the 
mitochondrial apoptosis by the BCL-2 family could be an important part of the drug 
resistance mechanism (also see section below and [1]). Furthermore pro-survival signaling by 
the PI3K-AKT-mTOR axis could contribute to increased resistance to apoptotic signaling in 
steroid resistant cells. The downstream targets of PI3K-AKT are numerous [50]. In particular, 
critical interactions between pro-and anti-apoptotic regulators of the BCL-2 family can be 
modulated by AKT phosphorylation [51-52]. Similarly, AKT regulates the activity of 
downstream regulators of apoptosis such as the inhibitors of apoptosis protein (IAP) family 
[53]. Therefore both new agents that interfere with BCL-2-mediated suppression of apoptosis 
[54] or inhibit signaling events of the PI3K/AKT/mTOR axes [54] may act synergistically 
with other anti-leukemic agents.   
Overactivation of the PI3K/AKT/mTOR pathway 
Alterations of the phosphoinositide 3-kinase (PI3K)/AKT pathway (Figure 5), a central 
integrator of survival signals, were frequently detected in human tumors, including adult 
lymphoma and ALL [1-2, 55-56]. The mechanisms of AKT activation are multiple. In T-
ALL, PTEN phosphatase, negative regulator of PI3K, is often inactivated due to mutations 
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[57], deletions [58] or epigenetic inactivation. Inactivation of PTEN was shown to play a 
prominent role in resistance to NOTCH inhibition in T-ALL, an effect that appears to be 
mediated by AKT [56]. Activation of PI3K-AKT signaling can also occur by mutation of 
PI3K or AKT in T-ALL [59]. With gene expression profile on primary pre B-ALL, AKT 
signature was one of the most prominent and was associated with GC-resistance [1]. 
Furthermore, recent studies underlined the fact that stream regulators of the PI3K/AKT, such 
as Ras, PTPN11 or FLT3, [60-64] display mutation that might over-activate this pathway. 
Consistent with this, inactivation of AKT using arsenic trioxide (ATO), re-sensitized steroid 
resistant cells to dexamethasone. Furthermore, AKT was also shown to regulate members of 
the Inhibitors of Apoptosis Proteins IAP family, including XIAP and survivin, which are 
often abnormally expressed in leukemic cells, resulting in a blockade of caspase-dependent 
cell death pathways [2] [53]. 
Similarly, in acute myeloid leukemia various mutations were found in this signaling pathway, 
suggesting that aberrant activation of PI3K/AKT pathways might be of general interest in 
acute leukemia.  
mTOR pathway 
mTOR is a central protein involved in cell growth, proliferation, and survival [50]. mTOR 
can be found in two functionally distinct complexes (see Figure 5). The first, mTORC1 is 
thought to act downstream of AKT, is known to be inhibited by rapamycin, and regulates 
mRNA translation [65]. It can also inhibit AKT signaling pathway through a negative feed 
back loop, which may constitute a mechanism of escape for tumors cells when mTOR 
inhibitors are used for therapy [66]. The second, mTORC2, is thought to act upstream of 
AKT phosphorylating it on Ser473, or PKC, regulating cell proliferation and cytoskeleton 
organization [50] (Figure 5). In a bioinformatics approach, the mTOR inhibitor rapamycin 
was recently identified as potential modulator of the GC-response [1]. Rapamycin was shown 
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to improve the response to steroids in GC-resistant cell lines. This effect was proposed to be 
mediated by a modulation of MCL-1 levels [1]. In the work presented in my thesis, we could 
demonstrate that the mechanism involved is very different from the model proposed by 
Armstrong et al. Instead, rapamycin, when given in combination with dexamethasone, 
triggers the same non-apoptotic cell death pathway than the putative pan BCL2 antagonist 
obatoclax, which suggests that modulation of mTOR is important for induction of this 
autophagy-dependent pathway in steroid resistant ALL [67]. 
Figure 5: The PI3K/AKT/mTOR pathway. Mutations in this pathway are frequently found in leukemia. Inhibition of one of 
these components seems to sensitize multiresistant ALL cells to chemotherapeutics adapted from [54].  
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Chapter 2: Apoptotic cell death  
Many chemotherapeutic agents will eventually lead to apoptotic cell death via triggering the 
apoptotic pathway. Therefore the identification of the factors which contribute to an 
increased resistance to apoptosis may provide new rationales to develop therapeutic agents 
for chemomodulation. Apoptosis is a programmed cell death characterized by series of 
biochemical events that lead to a variety of morphological changes, including membrane 
blabbing, changes to the cell membrane such as loss of membrane asymmetry and 
attachment, cell shrinkage, nuclear fragmentation, chromatin condensation, and chromosomal 
DNA fragmentation [68].  
This process plays the main role in the regulation of tissue homeostasis, especially in cell 
systems characterized by a high turn over like the hematopoietic cells [69]. Deregulation of 
apoptotic process has been described as one of the hallmark of cancer [70]. Mechanisms that 
confer increased resistance to apoptotic signals may occur at many different levels of 
apoptotic regulation. Therefore the identification of the factors which contribute to an 
increased resistance to apoptosis may provide new rationales to develop therapeutic agents 
for chemomodulation. Apoptosis is distinguished in two different pathways, the extrinsic and 
the intrinsic pathway. 
Intrinsic apoptotic pathway 
The intrinsic pathway is under the control of the mitochondria activity [71] and the interplay 
between pro-apoptotic and anti-apoptotic members of the BCL-2 family at the mitochondria 
regulate execution of this apoptotic pathway. Depolarization of the mitochondrial membrane 
induced by apoptotic triggers results in the release of Cytochrome c. Subsequent formation of 
the apoptosome by recruitment of Apaf1 and Pro-Caspase-9 leads to the activation of 
Introduction 
19
Caspase-9. Activated Caspase-9 in turn activates Caspases-3, 6, and 7, proteases that herald 
demolition of the cell by cleaving numerous substrate proteins and activating DNases [68].  
BCL-2 family of proteins 
Key regulators of mitochondria membrane permeabilization are the BCL-2 family proteins. 
To date, 25 members of the BCL-2 family of proteins have been identified [72]. These 
proteins are localized to the mitochondria, the smooth endoplasmic reticulum[73], and 
perinuclear membranes [74]. Overexpression of several anti-apoptotic BCL-2 family proteins 
has been reported in hematologic malignancies, including leukemia [52]. BCL-2 family 
proteins are characterized by the presence of up to four relatively short sequence motifs, 
which are termed BCL-2 homology domains (BH) [72] (Figure 6). 
Figure 6: BCL-2 family of proteins 
BCL-2 family members can be divided into three subfamilies based on structural and 
functional features [71]. The anti-apoptotic subfamily contains the BCL-2, BCL-XL, BCL-
W, MCL- 1, Bfl1/A-1, and BCL-B proteins, which suppress apoptosis and contain all four 
BCL-2 homology domains, designated BH1-4. Some pro-apoptotic proteins, such as BAX, 
BAK, and BOK, contain Bcl-2 homology 1-3 domains and are termed ‘‘multidomain 
proteins,’’ whereas other pro-apoptotic proteins, such as BIM, BAD, and BID, contain only 
the BH3 domain and are termed ‘‘BH3-only’’ proteins [75].  
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The molecular surface of the anti-apoptotic BCL-2 builds a hydrophobic groove, the BH3 
binding cleft, which capable of binding the BH3 domain of the pro-apoptotic proteins. The 
variability of the amino acid composition of both pro-apoptotic BH3 domains as well as the 
residues lining the BH3-binding groove of the anti-apoptotic proteins dictate highly variable 
affinities for each specific pair of interactions. These affinities, combined with the spatial and 
temporal variations of the concentration of each of these protein-protein interactions. This 
complex interplay will regulate the pro-apoptotic activity of BCL-2 family members [76].  
Regulation of the intrinsic apoptotic pathway 
The principle site of action of the BCL-2 proteins is at the level of the mitochondria 
membrane (Figure 7). Anti-apoptotic BCL-2 family members such as BCL-2, -XL or MCL-1 
can prevent the activation of the multidomain pro-apoptotic family members, BAX and BAK 
, either directly, by sequestration other pro-apoptotic BCL-2 proteins, such as BIM, BID or 
BAD, which could directly activate BAK or BAX [77] (Figure 7). BAK is a mitochondrial 
membrane protein, while BAX is recruited to the mitochondria from the cytoplasm upon 
activation of apoptosis. BAX and BAK are required for the permeabilization of the 
mitochondria membrane [78]. Although the precise mechanism of permeabilization is 
debated, it results from a conformational change of BAX and BAK which will expose the N- 
terminal domain followed by the insertion in the mitochondria membrane as homo-
oligomerized multimers and the formation of a protein-permeable pore [79]. 
The BH3-only proteins can be activated by transcriptional induction, post-translational 
modification or liberation from endogenous inhibitors. They can exert their pro-apoptotic 
function at least through two different mechanisms. Some BH3-only proteins (so called direct 
activators such as BID or BIM) may activate the pro-apoptotic proteins directly initiating the 
apoptotic process either by stimulation of the translocation of BAX on the mitochondria or by 
a local effect on BAK [80]. Other BH3 (BAD or NOXA) preferentially interact with the anti-
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apoptotic proteins dissociating the direct activators from anti-apoptotic proteins which in turn 
activate BAX and/or BAK by oligomerization and mediate the mitochondria membrane 
permeabilization [80]. Oligomerization of BAX and BAX induces formation of a pore on the 
mitochondria membranes through which Cytochrome c and other factors are released [81]. 
Cytochrome c in the cytoplasm form a complex with Apaf1, resulting in recruitment and 
activation of Caspase-9. Caspases involved in apoptotic signaling are categorized into 
initiator and effector caspases [68]. To the family of  initiators belong Caspase-9 and 8 which 
recruit the signal from the Cytochrome c release or the activation of death receptor 
respectively and activate the effector caspases (Caspase-3, 7, 6) by proteolytic cleavage [82].  
Figure 7: Intrinsic apoptotic signaling pathway 
Extrinsic apoptotic pathway 
The extrinsic apoptotic pathway is mediated by death receptors [83]. Activation of the death 
receptor, by ligand binding, can induce apoptosis with or without involvement of 
mitochondria [83]. 
The death-receptor pathway is activated when members of the tumor necrosis factor (TNF) 
super-family bind to death receptors localized at the cell membrane [84]. Ligation of these 
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receptors initiates the formation of the multiprotein death-inducing signaling complex (DISC) 
[85].
The DISC complex consists of core proteins (FADD, TRADD, Caspase-8) and components 
that may mediate crosstalk with other pathways ((Daxx, FAP-1, FLASH, RIP1, FAF-1 and 
others). DISC formation results in activation of Caspase-8, which can propagate the signal by 
direct cleavage of the downstream target Caspase-3, or by cleavage of the BH3-only protein 
BID, which in turn translocates to the mitochondria induces BAX/BAK oligomerization, 
leading to the formation of the pore from which Cytochrome c is released [85] (Figure 8).  
Figure 8: Extrinsic apoptotic signaling pathway. 
Activation of death receptor signaling is complex and can induce three different cell 
responses based on cells types or physiological conditions. Induction of TNFR, for example, 
can result, as just mentioned, in apoptosis [86], cell survival through NF-kB activation [87], 
but also in alternative cell deaths [88].  
Targeting intrinsic apoptotic pathway 
Imbalance between members of the BCL-2 family of proteins has been proposed as an 
oncogenic mechanism [89-90]. The interaction between the BCL-2 anti-apoptotic with the 
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important to maintain the mitochondria membrane polarization. Therefore compounds that 
would interfere with regulatory interactions of pro- and anti-apoptotic proteins are of 
therapeutic interest. These interactions are mediated by the conserved BH3 domain and a 
hydrophobic pocket constituted by the BH1 and BH2 domain of BCL-2 proteins. Proof of 
principle for such an approach was achieved using a synthetic BID BH3 peptide, stabilized 
by hydrocarbon stapling (Figure 9) to reconstitute the native helical BH3 interaction domain 
[91], stapled peptides for the BH3 domain of pro-apoptotic BID displayed cytotoxic activity 
on ALL cells lines and delayed leukemia progression in a xenograft model [91-92].  
                                         
Figure 9: Hydrocarbon-stapled BH3 compounds [92] 
In order to restore apoptosis, a number of BCL-2 inhibitors have been developed to target the 
BH3-mediated interactions [93]. Using nuclear magnetic resonance screening, a small 
molecule BH3 mimetic, ABT-737, has been identified, that specifically binds into the 
hydrophobic groove of anti-apoptotic BCL-2 family members [94-95] (Figure 10A). ABT-
737 was shown to be effective as single agent in different cancer models including lymphoma 
and small lung cell carcinoma [96]. Furthermore it was shown to act synergistically with 
chemotherapeutics and radiation in these cells. A derivate of ABT-737 with better 
pharmacologic properties, ABT-263, is now in clinical development [97-98]. This agent 
however does not interfere with all BCL-2 family members. In particular, ABT-737 does not 
antagonize MCL-1. Several preclinical studies have shown that MCL-1 can mediate 
resistance to ABT-737 [99-101]. Given the postulated importance of MCL-1 in ALL [99, 
102] we suspected that ABT-737 may not be the ideal candidate to be used as 
chemosensitizer for this disease.  
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Figure 10: A: Crystal structure of the BCL-XL:ABT-737 complex (right) showing the binding pockets (p2 and p4) for the 
chloro-biphenyl and thio-phenyl groups of ABT-737 [95]. B: Predicted orientation of obatoclax within the BH3 binding 
groove of BCL-2 [103]. 
We therefore focused our attention on another compound, which was identified from a screen 
for small molecules that can interact with MCL-1 [103]. This small molecule, obatoclax 
[104], is an indole pyrrole derivative with very hydrophobic properties, which so far have 
prevented the exact characterization of the interaction with the supposed drug targets in vitro. 
In particular, there is no crystal structure available of this compound in complex with a BCL-
2 family member [103]. The predicted interaction with BCL-XL is depicted in Figure 10B. 
Biochemical and functional data using cell lines strongly suggest that obatoclax can disrupt 
the complexes between pro- and anti-apoptotic BCL-2 family members, in particular between 
MCL-1 and BAX [101, 103, 105-108]. As reported in publication 2 [3], obatoclax displays 
strong anti-leukemic activity at a sub-micromolar concentration. We showed that in 
combination with conventional chemotherapeutic agents, such as doxorubicine, cytarabine, or 
vincristine, sub-cytotoxic concentrations of these agents was sufficient to restore 
mitochondrial apoptosis. But unexpectedly, we discovered that this compound was also 
capable of very specific induction of a non-apoptotic cell death pathway in combination with 
glucocorticoids. This indicates that obatoclax interferes with critical cellular targets at the 
intersection of pro-survival and pro-death pathways. 
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Targeting the extrinsic apoptotic pathway 
The extrinsic pathway begins outside the cell through the activation of death receptors on the 
cell surface. These are triggered by specific molecules known as pro-apoptotic ligands. Pre-
clinical models showed clearly that the death receptor ligand TRAIL is effective in various 
cancer types including leukemia [109-114]. Resistance to TRAIL or to the CD95 ligand in 
leukemia is mainly due to inhibition of Caspases through members of the Inhibitor of 
Apoptosis IAP family in particular XIAP [115]. Fulda et al. showed that combination of a 
small molecule IAP inhibitor with ligands of the death receptor, leukemia cells were 
sensitized to CD95 or TRAIL [116-118]. TRAIL is already in clinical trial for non small cell 
lung cancer as single agent or in combination. This approach could therefore be of interest for 
combination therapy in ALL. 
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Chapter 3: Alternative cell death pathways in a context of defective 
apoptosis 
Besides apoptosis, two other alternative cell death pathways have been described, namely 
autophagy-dependent cell death, and programmed necrosis (necroptosis) [119-120]. These 
non-apoptotic forms of cell death have been described in cellular models in the context of 
defective apoptosis [120]. Apoptosis is ultimately executed by caspases. The use of caspase 
inhibitors has revealed the existence of alternative backup cell death programs for apoptosis 
in cell lines. The broad-spectrum caspase inhibitor zVAD-fmk modulates the three major 
types of cell death. Addition of zVAD-fmk blocks apoptotic cell death, sensitizes cells to 
necrotic cell death, and induces autophagic cell death.  
Autophagy 
In healthy cells, autophagy is a highly regulated cellular process by which cells recycle their 
own non essential, redundant, or damaged organelles and macromolecular components [121-
122]. It is under the control of ATG genes, which are conserved throughout evolution, 
suggesting their importance. During this process part of the cytoplasm is sequestered into 
autophagosomes and finally delivered to lysosomes for bulk degradation [123]. Beyond this 
homeostatic function [124-127], autophagy is a process by which the cells adapt their 
metabolism to starvation [128-131]. By catabolizing proteins and macromolecules, autophagy 
generates metabolites that are used by the cells as substrate for the bioenergetics needs. The 
functional relationship between autophagy and apoptosis is complex. Depending on the 
cellular context, autophagy occurs as a stress response to pro-apoptotoc signals and thereby 
can interfere with the action of chemotherapeutic agents or radiotherapy. The mechanisms by 
which autophagy promotes cell survival are not restricted to its role in maintaining cellular 
energy homeostasis during starvation. Autophagy is also involved in removing damaged 
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mitochondria and other organelles. In this context autophagy can promote cell survival also 
during aging, infection disease and neurodegenerative process. In fact increasing evidence 
underlines the cytoprotective role of autophagy that allows to increase tumor cell survival 
under conditions of metabolic stress and hypoxia as well as to escape chemotherapy-induced 
cell death. In breast cancer for example induction of autophagy protects cells from 
trastuzumab treatment [132]. However there is also clear evidence for the role of autophagy 
in programmed cell death [133-134] (see below).  
Regulation of the autophagic pathway 
The execution of autophagy is mediated by evolutionarily conserved proteins known as the 
autophagy-related (ATG) proteins [135]. So far, the systematic analysis of the expression 
patterns and transcriptional regulation of ATG genes has remained incompletely defined.
Among the approximately 30 autophagy-related (ATG) genes identified so far, there are two 
ubiquitin-like proteins, ATG12 and ATG8. Analogous to ubiquitination, ATG12 is 
conjugated to ATG5 by ATG7—an E1-like protein—and ATG10—an E2-like protein. 
Similarly, ATG7 and ATG3 are the respective E1-like and E2-like proteins that mediate the 
conjugation of Atg8 to phosphatidylethanolamine. Both ATG12–ATG5 and ATG8 localize to 
the developing autophagosome. The ATG12–ATG5 conjugate facilitates the lipidation of 
ATG8 and directs its correct subcellular localization. ATG8–phosphatidylethanolamine is 
probably a scaffold protein that supports membrane expansion and the amount present 
correlates with the size of autophagosomes [135-136](Figure 11).
Figure 11: Localization of the ATG proteins on the autophagosome 
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Regulation of autophagy induction through mTOR  
mTOR is an upstream negative regulator of this process [137-138]. Availability of cellular 
amino acids, especially branched chain amino acids such as leucine, or glucose levels 
regulate mTOR activity. In fact nutrient starvation, or low glucose availability inhibits the 
kinase activity of mTOR and induces autophagy. From this observation many studies have 
been performed in order to understand the connection between mTOR and autophagy. It has 
been shown that mTOR phosphorylates an upstream autophagy protein ATG13 inhibiting the 
formation of a complex in with UKL1 [139-140]. Inhibition of mTORC1 by rapamycin or by 
starvation, leads to dephosphorylation of ULK, and Atg13 in human cells which induces 
autophagy. These studies suggested that ULK and Atg13 could act as direct targets of 
mTORC1 [139-140]. 
An important element in the nutrient-signaling pathway upstream of mTORC1 involves 
hVps34 also named PI3KIII (phosphoinositide 3-kinase class III), a lipid kinase conserved 
throughout eukaryotes and key regulator of autophagy [141-142]. Deficiency of the 
mammalian hVps34 suppressed leucine-responsive activation of mTORC1, suggesting that 
hVps34 may act upstream of mTORC1 signaling [143] (Figure 12). Consistent with an 
important role of mTOR in the control of autophagy, a small molecule screen, performed to 
identify new pharmacologic inducers of autophagy identified mainly mTOR inhibitors [144]. 
Figure 12: Regulation of autophagy by mTOR and during vesicles nucleation 
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The autophagy gene Beclin-1 is a critical regulator. 
Beclin-1 was found in protein complexes that mediate very early steps of the autophagic 
process. Deletion of Beclin-1 prevents autophagy, underscoring the importance of this 
autophagy regulator [145]. Interestingly, evidence from mouse models suggests that Beclin-1 
can act as a haploinsufficient tumor suppressor, since Beclin-1+/- mutant mice suffer from a 
high incidence of spontaneous tumors [146]. This suggests that Beclin-1 could be involved in 
pathways that control tumor progression, in particular by contributing to cell death. 
Interestingly, Beclin-1 was also found to be a BH3-only protein and as consequence possibly 
to be regulated by BCL-2 anti-apoptotic proteins. The interaction of Beclin-1 with BCL-2 
anti-apoptotic proteins results in sequestration of Beclin-1 from PI3K class III complex and 
inhibition of autophagy [133]. The interaction of Beclin-1 and BCL-2 is thought to be weaker 
than the interaction of BCL-2 with other BH3 proteins [147-148]. Functionally, there is some 
evidence that disruption of Beclin-1 from BCL-2 by BAD or by micromolar concentrations 
of the BH3-mimetic ABT-737 can lead to induction of autophagy [149], suggesting the 
possibility that the BCL-2 family control mechanisms at the intersection of apoptosis and 
autophagy control. 
In the work submitted in this thesis, we have shown that sub-cytotoxic concentrations of 
obatoclax were sufficient to disrupt a complex between endogenous Beclin-1 and MCL-1 and 
that this phenomenon was associated with steroid re-sensitization. Our observation supports a 
model in which MCL-1 is part of a protein complex that is critical for the control of 
autophagy.  
Evidence for autophagy-dependent cell death 
In several reports functional data were provided that support a role for autophagy in cell 
death. In the central nervous system, ATG7 deficiency protected neurons from caspase-
dependent and caspase-independent cell death after hypoxic/ischemic brain injury [150]. In 
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human glioblastoma, knockdown of the autophagy genes ATG1 or ATG5 prevented the 
cytotoxic effect of cannabinoids, which induce autophagy-dependent cell death in via an 
mTORC1 dependent pathway [151]. In Bax-/-Bak-/- MEFs, and in BCL-2 over-expressing 
MEFs, cell death triggered by etoposide or staurosporine was dependent on autophagy genes 
Beclin-1 and ATG-5 [145]. Consistent with this, inhibition of cysteine proteases can cause 
autophagic cell death in selected cell types. For example in U937 monocytoid cells and 
macrophages that were treated with lipopolysaccharide, the inhibition of cysteine proteases 
with z-VAD-fmk induced autophagic cell death, which was attenuated by the RNA 
interference (RNAi)-mediated knockdown of beclin-1 [152]. This effect is likely to involve 
the combined inhibition of one or several caspases, including Caspase-8, as well as that of a 
protease from another class of cysteine proteases, most probably a calpain [153]. 
Furthermore, inhibition of caspases induces autophagy also in Jurkat cell lines treated with 
tumor necrosis factor alpha (TNFa). Furthermore recent insight from drosophila genetics 
indicate that the control of autophagy via mTOR is critical to induce regression of the 
salivary glands, which provides the first evidence for a critical role for autophagy-dependent 
cell death in development [154]. We now provide the first clear evidence for a role for 
autophagic cell death in cancer. 
A programmed form of necrotic cell death is relevant for tissue homeostasis and 
cancer 
A form of programmed necrosis has been reported by several groups to occur in 
circumstances where the normal apoptotic response is defective [155-158]. This alternative 
cell death pathway appears to be regulated by the receptor interacting protein (RIP1) [4]. 
RIP1 is a central kinase associated with death receptor-induced signaling complexes and 
represent a molecular switch between cell death and survival [155]. Tschopp et al discovered 
that in active lymphoblasts treated with FAS, the caspase inhibitor zVAD induced a form of 
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cell death with necrotic features, regulated by the kinase activity of RIP1. Consistent with 
this, studies in RIP1-deficient Jurkat cells, demonstrated that necroptosis, induced by death 
receptors ligands TNF, FAS or TRAIL in apoptotic-deficient conditions, depends on the 
presence of RIP1 [155, 159-161].  
RIP1 is essential for pro-survival and pro-death signaling 
RIP1 was first identified as a critical mediator of pro-survival signals. Consistent with the 
role of RIP1 in cell survival, mice lacking RIP1 display extensive apoptosis [162]. This effect 
appears to be related to the death receptor pathway. Deletion of RIP1 increases sensitivity to 
TNF induced cell death. RIP1 mediates this pro-survival effect via activation of NF-kB [163]. 
Activation of the TNF receptor, results in the recruitment of a protein complex to the receptor 
that includes RIP1 [163-164], which in turn results in activation of a wide range of target 
genes, which also include anti-apoptotic regulators (XIAP, cIAP and BCL-XL) [165-167], 
Cellular inhibitors of  apoptosis (cIAPs) have been shown to mediateRIP1 ubiquitination in 
this complex [165-166] (Figure 13).  
Figure 13: Regulation of NF-kB by TNFR 
Several groups have shown that RIP1 kinase function mediates the activation of a non-
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159]. A very specific inhibitor of RIP1 kinase has been identified (NEC-1), which constitutes 
a very useful tool for the investigation of RIP1 kinase function in vivo [157]. Besides RIP1, a 
functional RNA interference screen identified a number of genes that are required for 
programmed necrosis, some of which overlap with genes that also control apoptosis [168]. As 
expected this screen also identified the RIP1 regulator CYLD, whose essential function for 
the necroptotic pathway was validated by siRNA knock down experiments. Collectively, 
available data suggest that the ubiquitination status of RIP1 is a critical component of the 
molecular switch between pro-survival and pro-death signaling via RIP1. The molecular 
mechanisms of this switch are still poorly understood. The different RIP1 functions may 
involve different protein complexes. Activation of the death receptor induces internalization 
and formation of secondary cytosolic complexes, one dependent on TRADD adaptor protein 
(complex IIA) and one dependent on RIP1(Complex IIB) (Figure 14). The molecular events 
that result in activation of a necroptotic pathway when caspase-dependent cell death is 
blocked however remain to be elucidated. So far, it appears that a complex formed by FADD, 
Caspase-8, RIP1 and RIP3 induces necroptosis [169-170]. In fact it has been shown that 
interaction between RIP1 and RIP3 is important in order to induce necroptosis. RIP3 has 
been reported to act positively with many metabolic enzymes such as PYGL, GLUD1, and 
GLUL, this interaction induces formation of reactive oxidative stress (ROS) due to increased 
oxidative phosphorylation. Increased level of ROS induces methabolic stress which leads 
then to necroptosis [170].
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Figure 14: Death receptor induces autophagy or necroptosis 
Here I present our unanticipated discovery, that re-sensitization to the major anti-leukemic 
drug dexamethasone in highly resistant ALL is absolutely dependent on early induction of the 
autophagy pathway and strictly required RIP1 kinase dependent activation of necroptosis. We 
provide functional data for the importance of both pathway by showing complete rescue from 
re-sensitization after knock down of genes that are essential for apoptosis (ATG7, Beclin-1) 
and for necroptosis (RIP1, CYLD). We also show that modulation of mTOR is critical for 
this cell death pathway, which is consistent with our earlier data, demonstrating a pivotal role 
for the hyperactivity of the AKT pathway in drug resistant ALL. This work places cellular 
events that modulate autophagy and the necroptotic pathway in a new perspective in the 
context of highly resistant disease and point toward major perturbations in drug resistant ALL 
at the intersection of metabolic pathways, apoptosis and necroptosis. We will discuss the 
implications of our findings from the mechanistic and molecular standpoint, and the 
immediate implications for the clinical development of this promising therapeutic strategy.
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Subject of Investigation 
Childhood acute lymphoblastic leukemia is the most recurrent cancer in childhood. 
Nowadays, with the current treatments, about 80% of the patients are cured. However 20% of 
the patients are refractory to initial chemotherapy or they relapsed. Resistance to the first 
seven days of treatment with steroids is one of the most important prognostic factors of poor 
outcome. Steroid resistance has been suggested to be due to an apoptotic blockade, resulting 
from either overactivation of PI3KI or overexpression of BCL-2 anti-apoptotic proteins. We 
aimed to investigate new strategies in order to overcome steroid resistance in ALL. 
1) Low-dose arsenic trioxide sensitizes glucocorticoid-resistant acute 
lymphoblastic leukemia cells to dexamethasone via an Akt-dependent pathway. 
(Article 1)
In this (second authorship) paper we characterized and revealed the mechanism of 
how inhibition of the PI3K/AKT pathway by using arsenic trioxide (ATO) sensitizes GC-
resistant ALL cells to dexamethasone. Combination of ATO with dexamethasone induced 
inhibition of AKT, which affected its downstream targets such as the BH3-only protein BAD 
and the endogenous Caspase inhibitor XIAP.  
2) Induction of autophagy-dependent necroptosis is required for childhood acute 
lymphoblastic leukemia cells to overcome glucocorticoid resistance. (Article 2)
In this (First authorship) paper, I evaluated the potential of a pan-BCL2 inhibitor 
called obatoclax, to sensitize steroid resistant cells to dexamethasone. The combination 
treatment resulted in activation of autophagy-dependent necroptosis. I also showed that 
obatoclax was able to sensitize primary cells of VHR-ALL patients to daunorubicine, 
vincristine and cytarabin. In this context cell death had apoptotic features. I also showed that 
the combination treatment with dexamethasone and obatoclax was effective in vivo in our 
refractory leukemia xenograft model.  
This article is the main part of my work and thus will be the essential part in the discussion 
and outlook section. 
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Contribution to the papers:  
  
Publication 1: 
For this publication my contribute was to prove that the decrease in cell prolipheration, 
observed in MTT assay, in steroid resistant cell lines upon treatment with dexamethasone and 
arsenic trioxide (ATO), was due to increase of cell death. I performed annexin V PI stainig 
and caspase 3 activation assay.  
Publication 2: 
For this publication on which is based my PhD project, my contribution was: 
Experimentally: 
I performed all the experiments published except for: 
Figure 6 A/B/C 
The experiments showed in this figure were performed by Dr.Beat Bornhauser. 
Figure 8 C: Animals were transplanted intrafemorarly by Dr. Beat Bornhauser.  
Animal treatment was shared between me and Dr. Beat Bornhauser. 
Planning:  
Experiments were planned and designed by me, Dr. Bornhauser and PD. Bourquin 
The papers were written by Dr. Bornhauser and PD. Bourquin. 
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Results 
Low-dose arsenic trioxide sensitizes glucocorticoid-resistant acute lymphoblastic 
leukemia cells to dexamethasone via an AKT-dependent pathway.  
Bornhauser BC, Bonapace L, Lindholm D, Martinez R, Cario G, Schrappe M, Niggli FK, 
Schäfer BW, Bourquin JP. 
Blood. 2007 Sep 15;110(6):2084-91.  
Abstract
Incorporation of apoptosis-inducing agents into current therapeutic regimens is an attractive 
strategy to improve treatment for drug-resistant leukemia. We tested the potential of arsenic 
trioxide (ATO) to restore the response to dexamethasone in glucocorticoid (GC)-resistant 
acute lymphoblastic leukemia (ALL). Low-dose ATO markedly increased in vitro GC 
sensitivity of ALL cells from T-cell and precursor B-cell ALL patients with poor in vivo 
response to prednisone. In GC-resistant cell lines, this effect was mediated, at least in part, by 
inhibition of AKT and affecting downstream AKT targets such as BAD, a pro-apoptotic 
BCL-2 family member, and the X-linked inhibitor of apoptosis protein (XIAP). Combination 
of ATO and dexamethasone resulted in increased BAD and rapid down-regulation of XIAP, 
while levels of the anti-apoptotic regulator MCL-1 remained unchanged. Expression of 
dominant-active AKT, reduction of BAD expression by RNA interference, or overexpression 
of XIAP abrogated the sensitizing effect of ATO. The inhibitory effect of XIAP 
overexpression was reduced when the AKT phosphorylation site was mutated (XIAP-S87A). 
These data suggest that the combination of ATO and glucocorticoids could be advantageous 
in GC-resistant ALL and reveal additional targets for the evaluation of new anti-leukemic 
agents. 
For detailed information see attached manuscript 1.  
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Induction of autophagy-dependent necroptosis is required for childhood 
acute lymphoblastic leukemia cells to overcome glucocorticoid resistance.  
Bonapace L*, Bornhauser BC*, Schmitz M, Cario G, Ziegler U, Niggli FK, Schäfer BW, 
Schrappe M, Stanulla M, Bourquin JP. 
J Clin Invest. 2010 Apr;120(4):1310-23. *equal contribution 
Abstract
In vivo resistance to first-line chemotherapy, including to glucocorticoids, is a strong 
predictor of poor outcome in children with acute lymphoblastic leukemia (ALL). Modulation 
of cell death regulators represents an attractive strategy for subverting such drug resistance. 
Here we report complete re-sensitization of multidrug-resistant childhood ALL cells to 
glucocorticoids and other cytotoxic agents with subcytotoxic concentrations of obatoclax, a 
putative antagonist of BCL-2 family members. The reversal of GC-resistance occurred 
through rapid activation of autophagy-dependent necroptosis, which bypassed the block in 
mitochondrial apoptosis. This effect was associated with dissociation of the autophagy 
inducer beclin-1 from the anti-apoptotic BCL-2 family member myeloid cell leukemia 
sequence 1 (MCL-1) and with a marked decrease in mammalian target of rapamycin (mTOR) 
activity. Consistent with a protective role for mTOR in GC-resistance in childhood ALL, 
combination of rapamycin with the glucocorticoid dexamethasone triggered autophagy-
dependent cell death, with characteristic features of necroptosis. Execution of cell death, but 
not induction of autophagy, was strictly dependent on expression of receptor-interacting 
protein (RIP1) kinase and cylindromatosis (turban tumor syndrome) (CYLD), two key 
regulators of necroptosis. Accordingly, both inhibition of RIP-1 and interference with CYLD 
restored GC-resistance completely. Together with evidence for a chemosensitizing activity of 
obatoclax in vivo, our data provide a compelling rationale for clinical translation of this 
pharmacological approach into treatments for patients with refractory ALL. 
For detailed information see attached manuscript 2.
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Discussion & Outlook 
In my thesis I describe two pharmacological approaches to specifically bypass the apoptotic 
blockade to chemotherapy in multidrug resistant ALL cells. From a mechanistic standpoint, 
our results indicate that in the context of resistant cancer cells, interference with mechanisms 
that are at the intersection of pro-survival and pro-death regulation can restore programmed 
cell death to anti-leukemic drugs. 
The molecular mechanisms of drug resistance are still poorly understood in ALL. Resistance 
to apoptotic stimuli constitutes one of the hallmarks in cancer [171-172]. We and others [3, 
38] provide evidence for a blockade in the apoptotic response to dexamethasone in steroid 
resistant ALL cells. Despite decades of research, the anti-leukemic mechanism of 
glucocorticoids remains largely unknown. Glucocorticoids induce the intrinsic apoptosis 
pathway in ALL cells [173-174]. Resistance to Glucocorticoids could occur at many levels. 
Glucocorticoid resistance in primary ALL cells does not seem to be related to decreased 
expression or mutations of the GR [175]. Consistent with this, a screen for nucleotide 
variations using a PCR/single-strand conformational polymorphism sequencing strategy 
demonstrated that polymorphisms but not somatic mutations in the GR gene coding region 
occur in leukemic blasts of children with ALL. These data suggest that these genetic 
variations are not a major contributor for differences in cellular response to glucocorticoids in 
childhood ALL [45]. 
The principal gateway to mitochondrial apoptosis is controlled by the BCL-2 family of 
proteins. Anti-apoptotic activity of BCL-2 family members can be modulated by increasing 
transcription or stability [176-181]. Accordingly, imbalance between pro- and anti-apoptotic 
BCL2 proteins has been shown to contribute to increased resistance to anti-leukemic therapy 
[182-183]. For instance, the anti-apoptotic protein BCL2 was required for maintenance of 
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leukemia in a mouse model [90]. In the specific context of steroid resistance in childhood 
ALL, anti-apoptotic MCL-1 was shown to be overexpressed in primary ALL cells as part of 
the gene expression signature associated with in vitro GC resistance [184]. Deletion of BIM 
and/or PUMA or overexpression of BCL-2 or MCL-1 conferred GC-resistance in murine 
lymphoid cells [89]. Furthermore, dexamethasone was suggested to cause cell death through 
an increase of BIM levels in steroid-sensitive ALL cell lines [185]. To evaluate the 
involvement of the BCL-2 anti-apoptotic proteins in steroid resistant ALL cells with the idea 
to target these, many compounds were proposed. Peptides and BH3 mimetic compounds are 
becoming increasingly popular in a pipeline of products as pro-apoptotic anti-cancer drugs. 
The stabilized alpha helix stapled peptides (SAHB, [91]) represent an intriguing way to gain 
entry to the complex cascades of protein-protein interactions in the cell-death pathway. This 
is because they can theoretically retain structural and functional properties of native apoptotic 
proteins. 
The potential of these peptides to induce apoptosis in steroid resistant ALL cells was 
demonstrated in vitro and in vivo [92]. Native BH3-only proteins exhibit selectivity in 
binding pro-survival members, as do stapled peptides and small molecules that block these 
interactions. In particular it was proposed that BAD binds BCL-2 but not MCL-1. Based on 
this knowledge, our unpublished data demonstrate that only BID and BIM but not BAD 
SAHB can induce cell death in steroid resistant ALL as single agent but also in combination 
with dexamethasone. Moreover, low dose of obatoclax, but not ABT-737, sensitizes steroid 
resistant cells to dexamethasone. These data underline the possible role of MCL-1 in a 
context of GC-resistance in ALL and suggest that obatoclax sensitizes through a mechanism 
which may involve inhibition of MCL-1. Surprisingly, we found that steroid re-sensitization 
by obatoclax did not occur through activation of the classical intrinsic apoptosis pathway, 
since no mitochondria membrane depolarization occurred, Cytochrome c was not released 
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and Caspases 3 and 9 were not activated. Instead, cell death occurred through autophagy-
dependent induction of programmed necrosis, also referred to as necroptosis. It is well known 
that BCL-2 family of protein can regulate autophagy. Nutrient starvation, which is a potent 
physiologic inducer of autophagy, can stimulate the dissociation of Beclin- 1 from its 
inhibitors, by activating BH3-only proteins (such as BAD) [149]. Maiuri et al demonstrated 
that ABT-737, as well as BAD, is able to disrupt the interaction between BCL-2 and Beclin-
1, resulting in autophagy induction [149]. Consistent with this, we demonstrated that in 
steroid resistant ALL cell lines MCL-1 binds Beclin-1. Furthermore we found that 
subcytotoxic concentration of obatoclax, but not ABT-737 can disrupt this complex, 
suggesting that obatoclax could sensitize steroid resistant ALL cells by inhibiting MCL-1 and 
inducing autophagy. More experiments are needed in order to understand whether the effect 
of obatoclax on the protein containing MCL-1 and Beclin-1 results from a direct interaction 
or is secondary to other mechanisms and whether or not true BH3 mimesis is involved in this 
process. In our hands, functional experiments with MCL-1 knock down and overpression 
were not conclusive due to strong effects on cell cycle and apoptosis. Taken together these 
results suggest that obatoclax sensitizes steroid resistant cells to dexamethasone through a 
mechanism which involves autophagy and requires MCL-1.  
Autophagy is known as physiological mechanism which can rescue cells from apoptosis. 
More controversial is its involvement in cell death. Autophagy can occur to rescue cells from 
cell death. Indeed it was reported in many papers that both pharmacological inhibitors of 
autophagy and siRNAs that target essential modulators of the autophagic machinery have 
been shown to sensitize cancer cells to a wide spectrum of stress conditions, including (but 
not limited to): glucose and amino acid deprivation [186-187] growth factor withdrawal 
[188]; detachment from the extracellular matrix (i.e., anoikis) [189]; estrogen receptor 
Discussion & outlook 
41
antagonism with tamoxifen  [190]; radiation therapy [191]. Autophagy can also be a 
mechanism of cell death in a context of apoptosis-deficiency. Consistent with this, as 
mentioned in the introduction, in Bax/Bak DKO MEF, representing a background of 
apoptosis blockade, etoposide induces autophagic cell death. The fact that oncoproteins and 
tumor suppressor proteins from the BCL-2 family also control autophagy further 
substantiates the notion that tumor development may be favored by autophagy inhibition. We 
discovered that in steroid resistant ALL combination treatment with dexamethasone and 
obatoclax induces autophagy-dependent cell death. In this case induction of autophagy seems 
to be required to induce cell death. Consistent with this, pharmacological inhibition of 
autophagy, by using the PI3KCIII inhibitor 3-MA or Bafilomycin, or genetically inhibition, 
by downregulation of Beclin-1 and ATG7, completely blocked steroid sensitization in GC-
resistant cell lines and refractory ALL primary cells. Moreover, combination of 
dexamethasone and obatoclax inhibited clonogenic growth of GC-resistant ALL cells. 
Interestingly, we observed that in steroid resistant ALL cells, sensitization to dexamethasone, 
by different drugs occurred through induction of autophagy. Rapamycin [1] and arsenic 
trioxide [2] have been shown to be GC-sensitizers in steroid resistant ALL. It is known that 
rapamycin induces autophagy through inhibition of mTOR [1, 192-193], whereas ATO was 
shown to induce autophagic cell death in apoptosis-resistant glioma cell lines [194]. We also 
observed (data not published) that the autophagy inhibitor 3-MA prevents the steroid-
sensitizing effect of these two drugs. It is important to note that rapamycin and ATO both 
interfere with the PI3K/AKT/mTOR axis. Overactivation of the AKT pathway was proposed 
to contribute to chemoresistance in ALL. Constitutive activation of this pathway induces 
mTOR activity and therefore inhibition of autophagy in resistant disease. We therefore 
hypothesized that GC-resistant cells could be primed for mTOR-controlled autophagy. 
Indeed we reported that treatment with dexamethasone and obatoclax induces 
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dephosphorylation of a downstream target of mTOR, s6 protein, in resistant cells. This effect 
appears to be specific to the combination with glucocorticoids and induction of autophagy-
dependent cell death. Indeed, induction of apoptotic cell death by the combination of 
obatoclax with other cytotoxic agents was not associated with modulation of mTOR activity 
in refractory ALL. Taken together these data suggest that in steroid resistant ALL cells, 
induction of autophagy-dependent cell death is peculiar for the combination treatment with 
dexamethasone and obatoclax. Interestingly during Drosophila morphogenesis, the steroid 
ecdysone induces autophagic cell death in salivary glands, suggesting as well a role for 
steroids in inducing an autophagy-dependent cell death pathway. However other 
investigations have to be performed in order to clarify this point and the mechanism by which 
obatoclax induces apoptosis in combination with other cytotoxic agents. But the assessment 
of the phosphorylation status of mTOR targets may constitute a valuable biomarker to 
determine the biological response in patients treated with the combination of obatoclax and 
dexamethasone. 
We have shown that induction of autophagy is required for execution of programmed 
necrosis in ALL cells. This provides one of the first evidence for the importance of this 
emerging pathway in cancer. This non-apoptotic form of cell death appears to be tightly 
controlled [168]. Necroptosis constitutes a form of programmed cell death, because it does 
depend on the function of specific regulators [157]. So far this phenomenon has only been 
observed in a cellular context where apoptosis is blocked. It has long been known that 
lymphocytes induce non-apoptotic cell death upon alteration of specific apoptotic proteins 
such as Caspase-8 or FADD. In lymphoid cells that fail to activate Caspase-8 during T cell 
mitogenesis, a hyperactive autophagic state was induced followed by programmed necrotic 
cell death [120] which was dependent on RIP-1 kinase [155, 158, 195]. Consistent with this, 
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Degterev and his group showed that silencing of RIP1 or inhibiting its kinase activity with 
Necrostatin-1 (NEC-1) [157, 196] blocks necroptosis induced by TNF and zVAD [157, 197] 
in lymphoid cells. Here we show by electron microscopy that cell death induced by 
dexamethasone and obatoclax is characterized by autophagosomes formation and necrotic 
features. This pathway did strictly depend on RIP1, because knock down or inhibition of 
RIP1 reverted steroid sensitization completely. Ubiquitination status of RIP1 appears to 
determine the switch from pro-death to pro-survival signaling. One of the main regulator of 
this process is the deubiquitinase enzyme CYLD [198]. Consistent with previous information 
showing that RIP1 needs to be ubiquitinated to interact with survival targets [199], we 
confirmed that by silencing CYLD, necroptosis induced by double treatment was prevented. 
This is consistent with functional data by others, detecting RIP1 and CYLD as essential genes 
for the necroptotic pathway [168].  
Our studies highlight that necroptosis and autophagy are interconnected and that stimulation 
of autophagy is necessary to induce necroptotic cell death. It is still unclear which genes act 
upstream of RIP-1 and which are the targets of RIP-1 kinase activity. Interestingly, the 
cellular sensitivity to necroptosis appears to be connected to cellular pathways that mediate 
innate immunity.  
As ALL cells derive from early progenitors of lymphoid cells, it is conceivable that activation 
of pathways that have evolved as a response to pathogens could also be essential for 
oncogenesis. Necroptosis has been proposed as a salvage cell death pathway in cells that 
would be prevented to undergo apoptosis in the event of a viral infection [200].Consistent 
with the connection of necroptosis and innate immunity, cell death induced by activation of 
TLR3 in L292 cells in presence of INF requires RIP1 kinase activity to induce necroptosis. 
Bell et al proposed that as with other forms of danger (in this case damage organelles, 
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nutrient starvation, macromolecular structures) as detected by TLRs, autophagosome 
formation itself lead to the activation of signaling pathway that allows the cells to respond to 
intracellular stressors, if the source of “danger” overrides autophagy, cells respond in 
induction of cell death [169].Cell death can have apoptotic features or necroptotic in case of 
block in the apoptotic pathway. Consistent with this, Hitomi et al showed that in the context 
of caspase inhibition, stimulation of the TNF receptor pathway triggered necroptosis in L929 
mouse fibrosarcoma and in Jurkat ALL cells. In this model, knocking down or inhibiting 
RIP1 kinase activity, autophagy is prevented, which suggest a crosstalk between the two 
pathways. There is only very limited knowledge about a molecular connection between 
autophagy and necroptosis. Recent studies demonstrated the presence of a complex including 
elements of the DISC complex (FADD and Caspase-8) together with RIP1 on preparation of 
autophagosome membranes, in the association with ATG5/13 [201-202]. We propose that 
such a complex could possibly be central in mediating apoptotic cell death. In absence of the 
activation of Caspase-8 by cleavage in ALL cells undergoing necroptosis, this raises the 
question of a non-apoptotic function of Caspase-8 in a complex that includes RIP1.  
We plan to further investigate the molecular mechanisms involved in necroptosis induction in 
the context of steroid resistant ALL by two different approaches. First we will take advantage 
of RIP-1 and Caspase 8 deficient ALL cells to perform which we can rescue with engineered 
RIP-1 or Caspase-8 genes. This will enable us to perform tandem affinity purification of 
multiprotein complexes for mass spectrometry to detect specific changes of complexes that 
contain RIP-1 and Caspase-8 on and off obatoclax and dexamethasone in steroid resistant 
cells. Second we plan to optimize transfection of primary ALL cells to perform synthetic 
lethal screens in order to identify the genes that are essential for induction of the necroptotic 
pathway with this treatment. In our leukemia xenograft mouse model of refractory ALL 
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primary cells, we demonstrated that the treatment with obatoclax in combination with 
dexamethasone was effective. We observed durable remission with one year of follow-up, 
indicative of strong antileukemic activity.  
The results of my thesis show that steroid in combination with obatoclax induces autophagy-
dependent necroptosis. It is likely that obatoclax act as steroid sensitizer through induction of 
autophagy, furthermore, in this context mTOR activity decreases. Obatoclax sensitizes also to 
other chemotherapeutics, but the resulting cell death has apoptotic features suggesting that 
the mitochondria or the death receptor are involved. It is still unclear how RIP1 kinase is 
primed to induce necroptosis in this context. In Figure 15 the summary of my research is 
represented.  
Figure 15: Summary of the research
From a clinical standpoint, our data provide compelling evidence for the evaluation of 
chemomodulation using obatoclax in refractory ALL. This work has raised sustained interest 
within the community of experts in the field of pediatric leukemia. With the support of the 
drug resistant disease committee of the international BFM study group, a clinical protocol for 
a phase I trial with obatoclax has been developed by my mentor, Dr. Jean-Pierre Bourquin. 
The goal of this trial is to establish the safety of the combination of obatoclax with 
dexamethasone in heavily pretreated patients with relapsed or refractory ALL. The proposal 
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has obtained first priority at the European level and will be conducted in collaboration with 
the European ITCC consortium (Innovative Therapies for Childhood Cancer) and under co-
sponsorship of the University of Zurich and of the Cancer Research UK Clinical Trials Unit, 
University of Birmingham, which coordinates all clinical trials in pediatric oncology in the 
UK. This will be a multicenter European trial, including 7-10 experienced larger oncology 
centers with experience in phase I trials.  
Based on pharmacokinetic data from adult phase I trials with obatoclax, we know that 
obatoclax concentrations that were sufficient for chemosensitization of resistant ALL cells in 
co-culture on bone marrow stromal cells can be achieved at doses that are inferior to the 
maximal tolerated dose in adults with hematological malignancies [203-204] which 
constitutes the basis to establish dose levels for the pediatric trial. An overview of the study 
design is presented in Figure 16. Besides ruling out limiting toxicities, it will be essential to 
provide evidence for biological activity of the combination of obatoclax and dexamethasone 
in vivo in patients. Indeed it will be impossible to recruit enough patients to obtain conclusive 
data about the clinical efficacy of this treatment. It is critical to obtain first safety data and 
pharmacokinetic data in children to then design a phase II treatment element to assess the 
effectivity of this combination in patients with relapsed ALL. The current concept shared 
among experts in the field would be to perform a therapeutic window to test this element in 
relapsed ALL patients before they get started with the current best available relapse treatment 
protocol. In vivo evidence for chemosensitizing activity will strongly support the design of a 
phase II study. Furthermore, a phase I trial is currently initiated by the North American by the 
Childrens Oncology Group (COG) to test the safety of obatoclax in combination with 
doxorubicine and vincristine. The two pediatric trials are designed to be complementary. 
Valuable information will be available for the combination of obatoclax with dexamethasone 
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and with other non steroidal drugs. Together this will enable the design of an experimental 
bloc with 3 to 4 drugs for the treatment of high risk relapsed ALL. Furthermore the European 
study will test a new dose schedule for obatoclax with the intention to provide more constant 
exposure to the drug over one week, which is the typical length for chemotherapy elements in 
clinical protocols for the treatment of relapsed ALL [205]. 
Figure 16: Design of the clinical trial. The proposed design allows for rapid dose escalation and to perform essential 
pharmacokinetic and biological studies. 
One critical part of the clinical phase I study as planned here concerns the assessment of 
biological activity of obatoclax in vitro and in vivo. Apart from following the effect of the 
treatment with obatoclax on leukemia cells by flow cytometry in treated patients (see Figure 
16), it will be essential to demonstrate in vivo activity with respect to induction of cell death 
in leukemia cells. We therefore aim to provide the basis for the evaluation of a biological 
response in treated patients and for the development of an in vitro assay to monitor response 
to treatment. 
Combination of obatoclax and dexamethasone results in induction of autophagy-dependent 
necroptosis. Morphological features allow identifying this cell death mode using transmission 
electron microscopy. We are currently developing this method to monitor ALL cells in the 
peripheral blood from patients. The idea is to fix samples from bone marrow punctures of 
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from peripheral blood, before isolation of lymphocytes by FACS based on forward-side 
scatter properties.  
The electron microscopy protocol which I have developed during my PhD study will serve as 
basis for protocol optimization (publication 2, Figure 7). In a multicentric clinical setting, 
samples from peripheral blood and bone marrow will have to be fixed in the hematology 
laboratory of the treating center and shipped to our laboratory for microscopy. The critical 
aspect of protocol optimization will be to determine experimental conditions to concentrate 
the leucocytes from the patient’s blood for imaging. I have established a cell line from a 
patient de novo resistant ALL patient after passage in mice which we can maintain and treat 
in liquid suspension cultures. With this model I will compare different approaches to prepare 
whole blood with different amounts of ALL cells for TEM. This approach will enable us to 
determine the minimal amount of leucocytes that are required for reliable detection of the 
necroptotic features by TEM. Indeed, the mean blast count after the first week of prednisone 
monotherapy in first line therapy is 0.36 x106/ml peripheral blood (Martin Zimmerman, 
statistician of the BFM study group). In the phase I trial the average blast count is expected to 
be higher than in patients at initial presentation and the time point to study the biological 
response to obatoclax treatment will be earlier. It is therefore realistic to test if 0.5-1.0 x105 
cells/ml are sufficient for TEM. Because the method will be used for a proof of principle 
study on a limited number of patients, the methodology needs to be sensitive, but we can 
afford time consuming and extensive microscopy. In a second step the setting of the clinical 
trial can be simulated using our leukemia xenograft model. Based on our current data from 
experiments with ALL cell lines, we estimate that the best time point to detect necroptotic 
features in patients may be after 72 hours of treatment. Xenografted mice will be treated as 
outlined in Figure 16 once more than 10% of leukemia cells are detectable in the peripheral 
blood by FACS (Figure 17).  
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Figure 17: Workflow to model in vivo monitoring of treatment response  
The second implication from my work for this clinical trial derives from my observation that 
only the combination of obatoclax and dexamethasone specifically results in strong inhibition 
of mTOR activity in resistant ALL patients. This opens a possibility to detect a specific 
modulation of a cellular marker using intracellular flow cytometry, which is a well 
established method by now [206]. This approach has been use to identify predictive phospho-
flow patterns that correlated with outcome in adult AML [207]. Inactivation of mTOR 
signaling could be used to assess treatment response in vitro, on ALL cells from patients that 
would be eligible for this type of experimental therapy. We have a large series of relevant 
samples in our xenograft bank to perform pilot experiments and establish a correlation 
between phosphor-flow patterns after perturbation with drugs in vitro and the in vitro
response to combination treatment. Provided a reproducible pattern emerges, phospho-flow 
cytometry could also be used to monitor the effect of the treatment on ALL cells during the 
trial.  
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Figure 18: Work flow to establish the phospho-flow cytometry panels.  
Collectively, the work performed during my doctoral studies contributed significantly to the 
development of a novel therapeutic strategy for drug resistant ALL. We have built a leukemia 
xenograft model that enable to perform functional studies with the leukemia samples that are 
directly relevant for translational research. We discovered a new cell death pathway that is 
specifically triggered in the context of steroid resistant leukemia. This observation opens an 
entirely new avenue for the investigation of steroid resistance in ALL. We provide 
convincing evidence for effective chemosensitization of different chemotherapeutic agents in 
refractory ALL. This effect was also validated with in vivo experiments using ALL cells from 
highly resistant patients. Finally, this work constituted the basis for the development of a 
phase I clinical trial, the first step for the clinical development of this approach. 
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to establish phospho-flow, introduce different perturbations that will modulate the targets to test:
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NEOPLASIA
Low-dose arsenic trioxide sensitizes glucocorticoid-resistant acute lymphoblastic
leukemia cells to dexamethasone via an Akt-dependent pathway
Beat C. Bornhauser,1 Laura Bonapace,1 Dan Lindholm,2 Rodrigo Martinez,2 Gunnar Cario,3 Martin Schrappe,3
Felix K. Niggli,1 Beat W. Scha¨fer,1 and Jean-Pierre Bourquin1
1Department of Oncology, Children’s Hospital, University of Zurich, Zurich, Switzerland; 2Department of Neuroscience, Biomedical Center, University of Uppsala,
Uppsala, Sweden; 3Department of Pediatrics, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany
Incorporation of apoptosis-inducing
agents into current therapeutic regimens
is an attractive strategy to improve treat-
ment for drug-resistant leukemia. We
tested the potential of arsenic trioxide
(ATO) to restore the response to dexa-
methasone in glucocorticoid (GC)–resistant
acute lymphoblastic leukemia (ALL). Low-
dose ATO markedly increased in vitro GC
sensitivity of ALL cells from T-cell and
precursor B-cell ALL patients with poor
in vivo response to prednisone. In GC-
resistant cell lines, this effect was medi-
ated, at least in part, by inhibition of Akt
and affecting downstream Akt targets
such as Bad, a proapoptotic Bcl-2 family
member, and the X-linked inhibitor of
apoptosis protein (XIAP). Combination of
ATO and dexamethasone resulted in in-
creased Bad and rapid down-regulation
of XIAP, while levels of the antiapoptotic
regulator Mcl-1 remained unchanged.
Expression of dominant-active Akt, reduc-
tion of Bad expression by RNA interfer-
ence, or overexpression of XIAP abro-
gated the sensitizing effect of ATO. The
inhibitory effect of XIAP overexpression
was reduced when the Akt phosphoryla-
tion site was mutated (XIAP-S87A). These
data suggest that the combination of ATO
and glucocorticoids could be advanta-
geous in GC-resistant ALL and reveal
additional targets for the evaluation of
new antileukemic agents. (Blood. 2007;
110:2084-2091)
© 2007 by The American Society of Hematology
Introduction
Poor response to 7-day monotherapy with prednisone is one of the
strongest predictors of adverse outcome for the treatment of
childhood acute lymphoblastic leukemia (ALL).1 Despite intensive
research efforts, the mechanisms underlying glucocorticoid (GC)
resistance in ALL are still poorly understood. GC resistance is
unlikely to be GC-receptor (GR)–mediated because mutations of
the GR are uncommon and alterations in GR expression or function
have not been detected in primary leukemia samples from GC-
resistant patients.2-4
Because most agents used in ALL treatment, including glucocor-
ticoids, induce programmed cell death (apoptosis), mechanisms
that lead to an increased antiapoptotic state in leukemic cells may
constitute an alternative explanation for GC resistance in ALL.
There is increasing evidence for abnormal apoptotic signaling in
GC-resistant ALL, involving members of the Bcl-2 family of
regulators of the intrinsic apoptotic pathway.5 The antiapoptotic
Bcl-2 family member Mcl-1 was overexpressed in primary ALL
cells as part of the gene expression signature associated with in
vitro GC resistance.6,7 Expression levels of the proapoptotic Bcl-2
family protein Bim were increased after exposure to GC in
sensitive cells.8-11 Interestingly, induction of Bim was markedly
attenuated in response to prednisone in GC-resistant primary ALL
cells that were amplified by xenotransplantation.2 Deletion of Bim
or Puma conferred GC resistance of normal lymphoid tissues in
mice.12 These studies suggest that an imbalance between proapo-
ptotic and antiapoptotic regulators may be involved in the resis-
tance mechanisms. In agreement with this hypothesis, overexpres-
sion of Bcl-2 or Mcl-1 rendered murine lymphoid cells resistant to
dexamethasone.13
An imbalance that favors an antiapoptotic state in leukemic
cells may result from constitutive activation of certain prosurvival
pathways. Alterations of the phosphoinositide 3-kinase (PI3K)/Akt
pathway, a central integrator of survival signals, were frequently
detected in human tumors,14 including adult lymphoma and ALL
cell lines.15-17 Akt is able to modulate a number of apoptotic
regulators directly. Phosphorylation of the Bcl-2 family member
Bad by Akt was shown to induce Bad sequestration by protein
14-3-3, thereby blocking its proapoptotic function.18 At the postmi-
tochondrial level, Akt phosphorylation stabilized levels of XIAP, a
member of the inhibitor of apoptosis protein (IAP) family that
inhibits caspases-3, -7, and -9.19 Response of lymphoma cells to the
PI3K/Akt inhibitor LY294002 correlated with a decrease in XIAP
protein levels,17 suggesting that XIAP may be a relevant target in
lymphoma. An important downstream effector of Akt is mTOR
(mammalian target of rapamycin).20 Inhibition of mTOR with
rapamycin sensitized multiple myeloma and ALL cells to dexameth-
asone,21,22 underscoring the importance of this pathway. Interest-
ingly, the effect of rapamycin in ALL cell lines was associated with
a marked decrease of the antiapoptotic regulator Mcl-1.21
Among therapeutic agents with a potential to inhibit Akt,
arsenic trioxide (ATO) is of interest for several reasons. The safety
profile of ATO for the effective treatment of acute promyelocytic
leukemia (APL) is well established.23-25 ATO was shown to bear
relevant cytotoxic activity on T-ALL cell lines,26,27 which may
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involve a broad range of mechanisms.28 Depending on the type of
malignancy studied, induction of oxidative stress and reactive
oxygen species production by ATO was associated with a perturba-
tion of the NF-B29,30 or the PI3K/Akt15 pathways. In ALL cell
lines, down-regulation of Akt by RNA interference increased the
cytotoxic effect of ATO, indicating that inhibition of this pathway
by ATO may be relevant for its effect on lymphoid malignancies.15
Given the broad range of mechanisms by which ATO could
interfere with apoptosis resistance, we decided to evaluate this
agent in combination with dexamethasone in GC-resistant ALL.
Here we provide evidence that low-dose ATO treatment acts as a
GC sensitizer in ALL and that this effect is dependent on inhibition
of Akt. These data are consistent with a role for XIAP and Bad,
2 direct targets of Akt, in ATO-induced GC sensitization.
Patients, materials, and methods
Cell culture
CEM-C7-14 and CEM-C1-15 were kindly provided by Dr E. B. Thompson
(University of Texas Medical Branch, Galveston, TX). We will refer to
these lines as CEM-C7 and CEM-C1 in the text. The CEM, MOLT-4 (no.
CRL-1582; ATCC, Manassas, VA), and Jurkat (no. TIB-152; ATCC) cell
lines were maintained in RPMI 1640 medium containing 10% heat-
inactivated fetal bovine serum, 2 mM L-glutamine, and 100 IU/mL
penicillin/streptomycin (both from Invitrogen, Carlsbad, CA).
Reagents
ATO was obtained from Sigma (Buchs, Switzerland); PD98059, from VWR
international (Dietikon, Switzerland); and dexamethasone, from Mepha
Pharma (Aesch, Switzerland). Rabbit antibodies were from Cell Signaling
Technology (Danvers, MA): anti-PARP (1:1000), anti-Bim (1:1000), anti-
Bid (1:1000), anti-XIAP (1:1000), anti-Akt (1:1000), anti-pAkt (pSer473,
1:1000), anti-Bad (1:1000), rabbit anti-pBad (pSer136, 1:1000), anti–
Bcl-XL (1:1000), anti-PUMA (1:1000), and anti-cIAP1 (1:1000). Rabbit
anti-cIAP2 (1:700) and antisurvivin were from R&D systems (Minneapolis,
MN). Rabbit antiactin (1:3000) and rabbit anti–Mcl-1 (1:3000) were from
Sigma, and mouse anti–Bcl-2 was from Dako (Glostrup, Denmark).
Expression vectors, siRNA, and transfection
Full-length human XIAP cDNA was subcloned into the expression vector
pEGFP-C1. Mutagenesis was performed by polymerase chain reaction
(PCR) on a subcloned XIAP fragment. For XIAP-S87A, we used the
primers 5-CACAGGAAAGTAGCCCCAAATTGCAG-3 and 5-AATTT-
GGGGCTACTTTCCTGTGTCTTCC-3; for the XIAP-S87E construct, the
primers 5-CACAGGAAAGTAGAGCCAAATTGCAG-3 and 5-AATTT-
GGCTCTACTTTCCTGTGTCTTCC-3 were used. The pEGFP-XIAP con-
structs and a myristoylated/palmitylated-HA-Akt construct31 were trans-
fected using nucleofection (Amaxa, Cologne, Germany). Transfection
efficiency was controlled using the pEGFP plasmid (Clontech, Mountain
View, CA) where appropriate. For nucleofection, 30 nM Bad siRNA (Bad
nucleotides 817-837 and 1033-1051, NM_004322; Silencer siRNA library,
cat no. 81 820; Ambion, Austin, TX) was used (solution v and Amaxa
program T-016).
Patient samples
Primary ALL cells were recovered in small portions from banked frozen
presentation samples on dry ice using a sterile scalpel and allowed to
recover in RPMI supplemented with 10% FCS, 5 g/mL insulin, 5 g/mL
transferrin, and 5 ng/mL sodium selenite (Sigma) for 4 hours. Cell viability
as determined by trypan blue exclusion after thawing was between 50% and
85%. Cells (5  104) were incubated in 100 L medium in round-bottom
96-well plates. Patients were enrolled in the ongoing ALL-BFM 2000
protocol and had given informed consent in accordance with the Declara-
tion of Helsinki. Approval was obtained from the institutional review board
of the Medical School Hannover for these studies. This IRB is the central
IRB for all participating centers in trial ALL-BFM 2000. In addition, the
studies have been approved by the local IRBs of each participating
institution, including the University Children’s Hospital Zurich. According
to ALL-BFM criteria, prednisone good-response (PGR) was defined as the
reduction of leukemic blasts in the peripheral blood to lower than 1000 per
microliter on day 8 after 7 days of monotherapy with prednisone. Minimal
residual disease (MRD) was measured after induction therapy on treatment
day 33 and after induction at week 12. MRD high risk is defined as a
persistent high MRD load at week 12 (103 or greater).
Treatment, MTT assay, and determination of apoptosis
Experiments were performed in 96-well plates with 2  104 cells per well.
Viability of cells was assessed using the cell proliferation kit (MTT) (Roche
Applied Sciences, Rotkreuz, Switzerland). The minimal absorbance of control
wells was OD 0.8. For primary patient samples, the trypan blue dye exclusion
assay was used to determine the effect of treatment on cell viability. Annexin-V
stainings were performed with FITC-labeled annexin-V and 1 mg/mL propidium
iodide (BD Biosciences, San Jose, CA). Briefly, treated 105 cells were washed in
cold PBS and then resuspended in 100 L binding buffer (10 mM HEPES/
NaOH, pH 7.4, and 140 mM NaCl2). Annexin-V–FITC and PI (5 L each) were
added and incubated at 4° in the dark for 30 minutes before flow cytometry
analysis (Beckman Coulter Cytomics FC500; Hialeah, FL). Caspase activity was
detected by CaspGLOW Red Active Caspase-3 Staining Kit (Alexis Platform,
Lausen, Switzerland) according to the manufacturer’s instructions. Briefly,
1 L specific substrate for caspase-3 (Red-DEVD-FMK) was added to 105
treated cells in 300 L of medium for 1 hour at 37°C and enzymatic
cleavage was analyzed by flow cytometry.
All experiments were performed in triplicate and repeated at least
3 times. Data analysis was done with the GraphPad prism software (San
Diego, CA) and statistical analysis using the Student t test.
Determination of cellular reactive oxygen species (ROS)
The generation of ROS was analyzed using 2-dichlorofluorescein diacetate
(DCFDA; Sigma). Cells (2  104) were incubated with ATO for 5 hours.
After incubation with 20 M DCFDA for 4 hours at 37°C, signals were
analyzed by fluorometry using filters for excitation at 485/20 nm and
emission at 530/35 nm. The results were normalized to total protein
expression levels and are shown as arbitrary fluorescent units.
Sodium dodecyl sulfate–polyacrylamide gel electrophoresis
(SDS-PAGE) and Western blot analysis
For Western blotting, whole-cell extracts were prepared from 1  106 cells
using radioimmunoprecipitation assay (RIPA) buffer (50 mM Tris-Cl, pH
6.8, 100 mM NaCl, 1% Triton-X-100, 0.1% SDS) supplemented with
complete mini protease inhibitor cocktail (Roche Applied Sciences) and
1 mM sodium orthovanadate (Sigma) for 20 minutes on ice. For detection
of primary antibodies, we used horseradish peroxidase–labeled goat
antirabbit or antimouse antibodies from Pierce Biotechnology (Rockford,
IL). Signal detection was performed using the chemiluminescence substrate
from Pierce Biotechnology, directly scanned with the ChemiGenius imag-
ing system (SynGene, Cambridge, United Kingdom) and quantified with
the GeneTools 3.1 image analysis software (SynGene).
Results
ATO augments the response to dexamethasone in
glucocorticoid-resistant acute lymphoblastic cell lines
In order to evaluate the potential of ATO for the treatment of glucocorti-
coid (GC)–resistant ALL, we selected a panel of T-ALL cell lines that
show different sensitivity to GC and established dose-response curves
for ATO and dexamethasone (Table 1). As expected from previous
reports,15,27,32 the GC-sensitive CEM-C7, and the GC-resistant CEM-
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C1, MOLT-4, and Jurkat cell lines were sensitive to ATO with IC50
values of 2.0, 1.8, 1.2, and 0.76 M, respectively. This concentration
range was safely achieved in the peripheral blood of adult APL
patients.33 Next, we performed combination experiments to evaluate the
sensitizing effect of ATO on dexamethasone. A concentration of 0.25
MATO was sufficient to resensitize all 3 GC-resistant lines (CEM-C1,
Jurkat, and MOLT-4) to dexamethasone (Figure 1A). At this concentra-
tion, ATO alone induced cell death in less than 5% of cells compared
with untreated controls. In contrast, the response to dexamethasone
could be augmented only slightly in GC-sensitive CEM-C7 cells (Figure
1A). We verified that increased cell death was indeed due to apoptosis
induction by using flow cytometry to detect increased phosphatidylser-
ine exposure and caspase activation in apoptotic cells (Figure 1B,C).
Single-agent treatment with dexamethasone resulted in increased an-
nexin-V positivity and caspase activation in the GC-sensitive CEM-C7
cells, but only slightly if at all in GC-resistant cells. Combination
treatment of dexamethasone with 0.25 M ATO increased annexin-V
positivity and caspase activation compared with controls with either
ATO alone or dexamethasone alone in GC-resistant cells, and to a lesser
extent in GC-sensitive cells (CEM-C7). The amount of PI-positive cells
was consistently low (between 0.3% and 4.5% of all the cells) with the
exception of CEM-C1 cells treated with the combination of ATO and
Dex, where 11.5%  0.85% of the cells were PI positive (Table S2). To
verify that the effect of ATO was independent of the p53 status in ALL
cell lines, we used the MDM2 antagonist nutlin-3, which induces
apoptosis by displacing p53 from MDM2 only when p53 function is
intact34 (Table 1; Figure S2, available on the Blood website; see the
Supplemental Materials link at the top of the online article). We found
GC-resistant T-ALLcells that are responsive toATO with (CEM, Jurkat)
and without (MOLT-4) functional evidence for a p53 mutation. We also
evaluated the effect of ATO in combination with agents that are
commonly used for ALL induction chemotherapy. All 4 T-ALL cell
lines were sensitive to asparaginase, vincristine, and daunorubicin and
their drug-response profile was not altered by combination with ATO
(Figure S1). To evaluate if glucocorticoid receptor (GR)–mediated
transactivation could also contribute to GC sensitization by ATO, we
performed combinatorial treatment experiments after transfection of a
GR-responsive luciferase reporter (Figure S3).As expected, dexametha-
sone treatment resulted in increased transactivation of the GR-
responsive reporter gene in GC-resistant cells, indicating the presence of
functional GR in these cells. ATO did not influence reporter transactiva-
tion, either alone or in combination with dexamethasone. These results
indicate that low-dose ATO can resensitize GC-resistant ALL cells to
dexamethasone via GR-independent mechanisms.
Low-dose ATO generates oxidative stress and, in combination
with dexamethasone, a reduction in Akt phosphorylation with
concomitant effects on Akt targets Bad and XIAP
Given that induction of intracellular ROSs is one of the putative
mechanisms of ATO-induced apoptosis in cancer cells, we deter-
mined the impact of different ATO concentrations on ROS genera-
tion (Figure 2A). Cells were treated with ATO concentrations of
0.25, 1, and 5 M, and ROS production was measured by
fluorometry. In GC-resistant cell lines, a 5-fold increase of ROSs
was detected both at subtoxic (0.25 M) and cytotoxic (1-5 M)
ATO concentrations. Since increased oxidative stress is commonly
associated with activated oncogenic signaling, we focused next on
the evaluation of key regulators of survival pathways. We first
evaluated Akt, based on reports of high levels of phospho-Akt in
lymphoblastic cell lines. Exposure to 1 M ATO led to a decrease
of phospho-ser 473 Akt, the activated phosphorylated form of Akt,
within 10 hours of treatment, whereas the overall Akt levels
remained unchanged (Figure 2B). We next focused on known Akt
targets, including Bad, a proapoptotic member of the Bcl-2 family
of intrinsic apoptosis pathway regulators,18 and the X-linked
inhibitor of apoptosis protein XIAP, a potent inhibitor of caspases.19
Exposure to 1 M ATO correlated with an increase in Bad protein
levels after 16 hours of treatment. Simultaneously, XIAP levels
were considerably decreased.
Table 1. Characteristics of the T- ALL cell lines included in
this study
Cell line
Characteristics CEM-C7 CEM-C1 Jurkat MOLT-4
IC50 DEX, M 0.8 10  10 10
IC50 PRED, M 1.8 100  100  100
ATO, M 2.0 1.8 1.2 0.76
GR status L753F het L753F het R477H het ?
p53 status het mut het mut het mut no mutation
Nutlin assay no effect no effect no effect inhibition
IC50s were calculated using Graphpad Prism software with triplicate values from
MTT assays. The GR mutation R477H was also found in families with generalized
resistance to GC, mutation L753F was found in the patient samples from which the
CEM line was derived, and probably is not relevant for GC-resistance in CEM-C1.
p53 mutations as reported in the literature. We determined the dose response curves
for nutlin-3 with the MTT assay.
het indicates heterozygous; mut, mutation; DEX, dexamethasone; and PRED,
prednisone.
? indicates mutation status unknown.
Figure 1. ATO sensitizes resistant T-ALL cell lines to
dexamethasone treatment. (A) Response to increasing
concentrations of dexamethasone (DEX) after 72-hour
incubation with or without 0.25 M ATO. Cell viability was
assessed using the MTT assay. (B) Apoptosis rates were
determined using annexin-V/propidium iodide stainings.
Cells were incubated for 48 hours (CEM-C1, CEM-C7, and
MOLT-4) or 72 hours (Jurkat) with control, 0.25 M ATO,
7.6 M Dex (or 0.1 M for CEM-C7), and the appropriate
combination and analyzed by flow cytometry. (C) Induction
of caspase-3 activity was assessed by flow cytometry. For
panel A, the measurements were normalized to untreated
controls, and for all experiments, values of 3 experiments are
shown as mean plus or minus SD; **P  .05 (Student t test).
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If modulation of Akt, Bad, and XIAP were relevant for the
synergistic effect observed with low-dose ATO and dexametha-
sone, then the combination treatment should have similar effects on
these targets as ATO alone. Combination treatment resulted in a
decrease of Akt phosphorylation and in an increase of Bad
compared with low-dose ATO treatment and similar to the effect
obtained with 1 M ATO alone (Figure 2C). Detection of PARP
cleavage as a measure of apoptosis appeared more pronounced in
the combination treatment when compared with the single agents.
A sharp decrease of XIAP levels occurred with 0.25 M ATO,
without detectable difference when dexamethasone was added.
Also included in our panel were a number of proapoptotic and
antiapoptotic regulators. As shown in Figure 2C, levels of the
proapoptotic BH3-only proteins PUMA, Bim, and Bid as well as
the antiapoptotic regulators Bcl-2, Bcl-XL, and Mcl-1 were
unchanged after exposure to ATO and dexamethasone. These
results indicate that inhibition of Akt is a possible mechanism of the
sensitizing effect of low-dose ATO on dexamethasone. Modulation
of Bad and XIAP may be relevant for this effect, although the effect
on XIAP could also be mediated by another ATO-dependent
mechanism. To verify whether other IAP family members were
affected, we analyzed the expression levels of survivin, c-IAP1,
and c-IAP2 after treatment with either ATO alone, dexamethasone
alone, or the combination of both. As shown in Figure 2C,
expression levels of these IAP family proteins were unchanged
suggesting that down-regulation of XIAP is a specific effect.
Transient expression of dominant-active myrAkt decreases
GC response in sensitive cells and interferes with the
GC-sensitizing effect of ATO
To verify the relevance of Akt inactivation for the GC-sensitizing
effect of ATO, we used a dominant-active myristoylated form of
Akt.31 We transiently expressed myrAkt for 24 hours in CEM-C1
cells and analyzed the effect on cell viability following treatment
with dexamethasone or the combination of ATO at 0.25 M and
varying concentrations of dexamethasone of 0.1, 1, and 7.6 M for
48 hours. Transient expression of myrAkt conferred complete
resistance to dexamethasone treatment and inhibited the sensitizing
effect of ATO to dexamethasone, rendering CEM-C1 resistant to
the combination treatment (Figure 3A). One would expect that
myrAkt expression would also alter the expression of the Akt
targets XIAP and Bad in this experiment. Indeed, myrAkt expres-
sion rescued XIAP protein levels, and Bad phosphorylation was
increased compared with mock-transfected cells (Figure 3B).
XIAP down-regulation was inhibited and Bad phosphorylation at
Ser136 was maintained at control levels when myrAkt-overexpress-
ing cells were incubated with the combination of ATO and
dexamethasone. These data indicate that Akt activity protects XIAP
from degradation induced by low-dose ATO and dexamethasone as
well as maintains Bad in its inactive phosphorylated state.
Since the members of the IAP family are transcriptionally
regulated by NF-B,35 we also evaluated the effect of ATO on
NF-B activation. Cells were stimulated with ATO, dexametha-
sone, or in combination, and the effect on nuclear translocation of
NF-B was analyzed. We could not detect any decrease in the
nuclear translocation of the p65 subunit of NF-B in this experi-
ment (Figure S3). Collectively, our results suggest that a pathway
involving Akt, XIAP, and Bad is affected as a result of exposure to
ATO and dexamethasone.
Figure 2. ATO treatment induces ROS production and dephosphorylation of Akt, which is associated with an increase of Bad and decrease of XIAP. (A) ROS
generation in CEM-C1 and -C7 was quantified by fluorometry with varying concentrations of ATO as indicated. Values of 3 experiments are shown as mean (SD); P equals .05
(Student t test). (B) ATO as single agent. CEM-C1 and -C7 cells were incubated for different times with 1 M ATO. Western blot analysis using whole-cell extracts from a
representative experiment is shown. Antiactin was used for loading control. (C) Combination for 5 hours of 0.25 M ATO with 1 M DEX in CEM-C1 and Jurkat cells; A indicates
ATO; D, DEX.
Figure 3. Transient expression of myrAkt impairs the sensitizing effect of ATO
on dexamethasone-mediated cell death. (A) Dominant-active myrAkt was tran-
siently expressed in CEM-C1 cells. MyrAkt rendered cells completely resistant to
dexamethasone treatment and reduced the effect of 0.25 M ATO on the cytotoxic
effect of increasing DEX concentrations (0.1 M, 1.0 M, 7.6 M). Values from
triplicate MTT assays are shown as mean plus or minus SD. (B) myrAkt expression in
CEM-C1 cells enhances the levels of Ser136 p-Bad and restores XIAP. Cells were
treated as indicated 24 hours after transfection. Whole-cell extracts were obtained
after 5 hours of drug exposure and analyzed by Western blot.
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Down-regulation of Bad and overexpression of XIAP confer
resistance to ATO-induced GC sensitization
To demonstrate that inactivation of Bad may play a role in GC
resistance, we knocked down Bad levels by RNA interference in
CEM-C1 cells (Figure 4A). A significant decrease of Bad was
observed with 2 different specific siRNAs, but not with a scrambled
control (Figure 4B), which correlated with a reduction of ATO-
mediated cytotoxicity at 1-M concentration (Figure 4C). As
expected, down-regulation of Bad affected the sensitizing effect of
low-doseATO in combination with dexamethasone, whereby one of the
specific siRNAs almost completely rescued the GC-resistance pheno-
type (Figure 4D). These results are consistent with the modulation of a
pathway involving Bad in GC sensitization, but imply that additional
mechanisms account for the full effect of ATO treatment.
Rapid down-regulation of XIAP due to loss of the stabilizing
phosphorylation on serine residue 87 could represent such a
mechanism. We therefore investigated the effect of XIAP overex-
pression on dexamethasone sensitization. To evaluate the relevance
of the Akt phosphorylation site, we mutated serine 87 to either
glutamine (XIAP-S87E, gain of function) or alanine (XIAP-S87A,
loss of function) as reported previously.19 As anticipated, overex-
pression of XIAP rendered CEM-C1 cells resistant to ATO-induced
GC-mediated cell death (Figure 5A). Despite overexpression levels
at 25% of wild-type XIAP, XIAP-S87E induced GC resistance to a
similar extent (Figure 5B). In contrast, XIAP-S87A expression was
clearly less effective at rescuing cells from ATO-induced GC-
sensitization at expression levels that were comparable to the S87E
mutant. The correlation of decreased XIAP levels with inhibition of
Akt phosphorylation could be explained by an effect on XIAP
protein turnover. Indeed, the dominant-active mutant XIAP-S87E,
which is less susceptible to proteasomal mediated degradation, was
able to restore the resistance phenotype at much lower expression
levels compared with the wild-type protein (Figure 5A,B). Collec-
tively, our results show that dephosphorylation of Bad and destabi-
lization of XIAP levels, as a consequence of Akt inhibition, are
important for the GC-sensitizing effect of ATO.
Combination of ATO with the mTOR inhibitor rapamycin
is not synergistic
Having established Akt as important mediator in the GC sensitiza-
tion, and given that mTOR is also a potential target of Akt, we
asked whether intrapathway inhibition of Akt and mTOR by
combination of rapamycin with ATO increases the GC sensitization
effect of ATO (Figure S4). As reported recently,21 rapamycin
augmented the GC sensitivity of resistant CEM cells, an effect that
was shown to be associated with decreased Mcl-1 levels. Indeed,
10 nM rapamycin sensitized CEM-C1 to dexamethasone with a
comparable efficiency with the results achieved with 0.25 M
ATO. However, combination of the 2 agents was not synergistic.
Thus, the 2 approaches appear to be equivalent but not complemen-
tary in the CEM cell-line model of GC resistance.
ATO improves glucocorticoid sensitivity of primary leukemic
cells from ALL patients with poor in vivo response to prednisone
In order to validate the results obtained in cell lines, we selected
pretreatment samples from 7 ALL patients at disease presentation
Figure 4. Down-regulation of Bad using
siRNA decreases the sensitivity of the cells
to the combination treatment of ATO and
dexamethasone. (A) CEM-C1 cells were trans-
fected with 2 distinct siRNAs directed against
Bad. Down-regulation of Bad was assessed
after 48 hours by Western blot. (B) Signal
quantification by densitometry. (C) siBad treat-
ment of CEM cells decreased the cytotoxic
effect of 1 M ATO as single agent and (D) of the
combination of low-dose ATO (0.25 M) with
DEX. A scrambled siRNA was used for control.
Triplicate results of the MTT assay are shown as
mean plus or minus SD; **P  .05 (Student t
test).
Figure 5. Resistance to ATO-mediated GC sensitization by XIAP overexpres-
sion requires the XIAP-S87 phosphorylation site. (A) Response to increasing
concentrations of DEX after 72-hour incubation in combination with 0.25 M ATO,
after transient transfection of different XIAP constructs as indicated and described in
“Patients, materials, and methods.” Triplicate results of the MTT assay are shown as
mean plus or minus SD. (B) Western blot with specific anti-XIAP antibody (top panel)
and an anti-GFP antibody (bottom panel).
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based on their prednisone response.1 We included 2 patients with
poor initial response to prednisone (PPR) and persistence of
minimal residual disease after induction chemotherapy (MRD-
HR), 2 patients with a PPR but low or no detectable MRD at week
12 (non–MRD-HR), and 3 patients with good response to pred-
nisone (PGR) (Table 2). We first determined the response to ATO as
a single agent in vitro (Figure 6A). At low concentration, ATO was
not cytotoxic for normal bone marrow leukocytes. The IC50 values
for ATO-sensitive leukemia cells (3 PPR, 1 PGR) were comparable
with the responses obtained in cell lines. Low-dose ATO treatment
clearly increased the dexamethasone sensitivity of T-ALL and
pre-B-ALL cells from prednisone poor-responder patients (Figure
6B, Pt 1-4), but not in cells obtained from the prednisone
good-responder patients (Figure 6B, Pt 5-7). This response was
observed in both T-ALL (Pt 1-2) and precursor B-ALL (Pt 3-4),
similar to the observations made in cell lines. These results indicate
that ATO sensitization to dexamethasone does occur in primary
cells from GC-resistant patients and suggest that combination
therapy with ATO might be beneficial for GC-resistant patients.
Discussion
We report here that subtoxic doses of arsenic trioxide (ATO) can
restore the sensitivity to dexamethasone in glucocorticoid (GC)–
resistant T and precursor B acute lymphoblastic leukemia cells and
provide evidence for the Akt/XIAP pathway as candidate target for
combinatorial therapy in GC resistance.
Characteristic profiles of activated survival signals can be detected in
leukemia.36,37 One of the key signaling nodes that is commonly
activated in human tumors is Akt.14 High levels of endogenous
phospho-Akt inALL cell lines correlated with an increased sensitivity to
the PI3K/Akt inhibitor LY294002,17 suggesting that this pathway may
be important for the survival of leukemia cells. Constitutive activation of
prosurvival pathways could contribute to drug resistance by promoting
the resistance to apoptosis. Recent gene expression profiling data
suggest that Akt might indeed play a role in GC-resistant ALL. Gene set
enrichment analysis revealed that among gene sets derived from the
BioCarta pathway database (San Diego, CA), the Akt pathway was the
Table 2. Patients characteristics
Characteristic
Patient no.
1 2 3 4 5 6 7
Age, y 9 2 13 13 3 3 2
Subtype T T pc-B pc-B T pc-B pc-B
Blast, d0 207 338 70 69 34 0.1 69
Blast, d8 127 1.8 5.7 1.8 0.7 0 0
Pred. resp* poor poor poor poor good good good
BM blast d0 92% 95% n/a 99% 87% 98% 96%
MRD† HR non-HR HR non-HR non-HR non-HR non-HR
Blast in Giga/L
T indicates T-ALL; pc-B, precursor-B-ALL; Pred. resp, prednisone response; BM, bone marrow; HR, high risk and n/a, not available.
* Prednisone poor response is defined as more then 1000 blasts/L at day 8 of prednisone therapy.
†HR MRD is defined as an MRD load of 103 or greater at week 12 of treatment.
Figure 6. ATO sensitizes primary leukemia cells from prednisone poor-responder patients to dexamethasone. (A) Effect of ATO as single agent on 7 ALL patients who
are described in Table 2. No cytotoxic effect could be detected in bone marrow leukocytes from a healthy donor at 0.33 M ATO. (B) Response to increasing concentrations of
DEX with or without 0.33 M ATO on ALL cells from prednisone poor responders with T-ALL (Pt 1-2), pre-B-ALL (Pt 3-4), from prednisone good responders with T-ALL (Pt 5)
and pre-B-ALL (Pt 6-7).
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most highly enriched set in GC-resistant pre-B-ALL samples.21 Because
different oncogenic events may result in activation of theAkt pathway,14
approaches to target this pathway may be more widely applicable and
not dependent on the presence of a particular mutation. Based on these
considerations, we postulated that the broad range of biologic activities
of ATO, including its potential to inhibit the Akt pathway,15 could offer
an advantage in combination therapy of GC-resistant ALL.
The recent report that single-agent ATO treatment did not
induce a clinical response in 11 adult patients with relapsed and
refractory ALL38 should not preclude further evaluation of this
agent in combination therapy in ALL. For example, combination of
ATO with the tyrosine kinase inhibitor imatinib resulted in more
efficient induction of apoptosis in chronic myelogenous leukemia
(CML).39 We have shown here that subtoxic concentrations of ATO
(0.25 M) increase the sensitivity to dexamethasone effectively in
GC-resistant cells, which is reflected by a level of ROS production
comparable with levels achieved at higher cytotoxic ATO doses
(1-5 M). This is relevant because toxicity on normal hematopoi-
etic tissues was not relevant using ATO concentrations below 0.5
M.40,41 Thus, lower doses of ATO may be sufficient to achieve
clinically relevant drug-sensitization effects.
Different pathways were altered by ATO treatment depending
on the type of hematologic malignancy studied, such as the MAPK
pathway in AML cells and the NF-B pathway in myelodysplastic
syndrome.30,42 This may reflect context-dependent differences in
signal transduction pathway activation and illustrates the potential
advantage to use an agent with such a broad target range. We found
evidence mostly for an implication of Akt and downstream Akt
targets in GC sensitization by ATO, but recognize that we have
examined only a subset of downstream effectors that have been
previously implicated in the response to ATO.28 Among other
possible mechanisms that we evaluated, we could not detect
changes in Erk phosphorylation or find evidence for NF-B
inhibition. In our hands, ATO treatment also did not result in nuclear
translocation of the apoptosis-inducing factor (AIF) (data not shown).
Our results show that ATO inhibits Akt activation and influences 2
important regulators of apoptosis, the proapoptotic Bcl-2 family mem-
ber Bad and a member of the inhibitor of apoptosis protein (IAP) family,
XIAP. Down-regulation of Bad by RNA interference decreased ATO-
mediated GC sensitivity suggesting that part of the ATO effect is
mediated through interference with the intrinsic apoptotic pathway via
Bad. We also provide data for a complementary mechanism at the
postmitochondrial level via regulation of XIAP, which strongly regu-
lates apoptosis by direct binding and inactivation of the caspases-3, -7,
and -9. XIAP was reported to be stabilized by Akt phosphorylation,
resulting in a decrease of ubiquitin-mediated protein degradation.19
Consistent with the hypothesis that Akt inhibition could influence XIAP
protein stability, we observed a sharp decrease of XIAP after ATO
treatment. Accordingly, overexpression of dominant-active myrAkt
restored the XIAP levels, which correlated with GC resistance. Further-
more, the presence of the Akt phosphorylation site on XIAP was
required for a complete reversion of the GC sensitization by ATO.
Down-regulation of XIAP levels could also be due in part to inhibition
of translation resulting from a decrease of mTOR activity, since mTOR
is a target ofAkt and a decrease of XIAP translation was reported as part
of the synergistic effect of rapamycin and dexamethasone combination
in multiple myeloma.22 However, this would not explain why other
IAPs, survivin, cIAP1, and cIAP2, were not affected by ATO treatment.
Nevertheless, our experiments identified the Bcl-2 family member Bad
and XIAP as candidate targets for combination therapy in drug-resistant
ALL and provide a rationale for the evaluation of more specific small
molecule inhibitors that target apoptotic regulators in GC-resistant
ALL.43,44
Given the crosstalk between mTOR and Akt,45 the ATO effect
could also be mediated via Akt-induced mTOR inhibition. Indeed,
recent data show that the mTOR inhibitor rapamycin increased the
sensitivity of CCRF-CEM cells to GC.21 This effect was associated
with down-regulation of the antiapoptotic regulator Mcl-1. How-
ever, we could not detect any effect of ATO-mediated Akt
inhibition on Mcl-1 levels, implying that either indirect inhibition
of mTOR was not relevant for the ATO effect or that Mcl-1
down-regulation may not be a direct effect of mTOR inhibition.
The combination of ATO and rapamycin did not increase the
sensitivity of CEM cells to GC. This suggests that the 2 agents
could have overlapping effects. However, rapamycin was shown to
revert the resistance phenotype conferred by myrAkt overexpres-
sion in GC-sensitive lymphoid cells only partially,21 indicating that
part of the resistance mechanism is independent of mTOR signal-
ing. Our results also indicate that down-regulation of Mcl-1 is not
essential for GC sensitization, supporting the concept that Mcl-1–
independent mechanisms are important. Among other Bcl-2 family
members that could be involved in GC resistance, a failure of Bim
induction has been described to occur in GC-resistant ALL cells.2
In our experiments, an increase in Bim isoform levels was not
detected in ATO-mediated GC sensitization.
Experiments with primary cells are indispensable to model drug
resistance in pre-B-ALL, due to the lack of representative cell lines. We
did detect a GC-sensitizing effect using low-dose ATO consistently in
GC-resistant samples, but not in GC-sensitive samples, both from
T-ALL and precursor B-ALL patients. This observation strongly sug-
gests that GC-resistant ALL cells may be addicted to prosurvival
pathways that can be influenced byATO treatment. Improved preclinical
models of de novo drug-resistantALL will be required in order to define
the profiles of pathway activation that may predict resistance to different
drugs in MRD-HR ALL and to test appropriate agents in combination
therapy. Our data indicate that combination of low-dose ATO with
glucocorticoids may be a valuable and affordable approach to improve
the treatment of GC-resistant ALL.
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In vivo resistance to first-line chemotherapy, including to glucocorticoids, is a strong predictor of poor out-
come in children with acute lymphoblastic leukemia (ALL). Modulation of cell death regulators represents 
an attractive strategy for subverting such drug resistance. Here we report complete resensitization of multi-
drug-resistant childhood ALL cells to glucocorticoids and other cytotoxic agents with subcytotoxic concentra-
tions of obatoclax, a putative antagonist of BCL-2 family members. The reversal of glucocorticoid resistance 
occurred through rapid activation of autophagy-dependent necroptosis, which bypassed the block in mito-
chondrial apoptosis. This effect was associated with dissociation of the autophagy inducer beclin-1 from the 
antiapoptotic BCL-2 family member myeloid cell leukemia sequence 1 (MCL-1) and with a marked decrease in 
mammalian target of rapamycin (mTOR) activity. Consistent with a protective role for mTOR in glucocorti-
coid resistance in childhood ALL, combination of rapamycin with the glucocorticoid dexamethasone triggered 
autophagy-dependent cell death, with characteristic features of necroptosis. Execution of cell death, but not 
induction of autophagy, was strictly dependent on expression of receptor-interacting protein (RIP-1) kinase 
and cylindromatosis (turban tumor syndrome) (CYLD), two key regulators of necroptosis. Accordingly, both 
inhibition of RIP-1 and interference with CYLD restored glucocorticoid resistance completely. Together with 
evidence for a chemosensitizing activity of obatoclax in vivo, our data provide a compelling rationale for clini-
cal translation of this pharmacological approach into treatments for patients with refractory ALL.
????????????
Resistance to the initial phase of chemotherapy, in particular 
poor response to glucocorticoids (GCs), is a strong predictor 
of adverse outcome for childhood acute lymphoblastic leuke-
mia (ALL) (1, 2). During the last decade, the cooperative Ber-
lin-Frankfurt-Muenster (BFM) study group has validated an 
effective risk stratification approach, which is based on the 
assessment of the in vivo response to chemotherapy by leuke-
mia-specific quantitative PCR. A group of patients at very high 
risk for relapse (VHR-ALL) can be identified based on persistence 
of minimal residual disease (MRD) (3). Because this is likely to 
reflect de novo resistance to multiple conventional antileukemic 
agents, combination treatment with new agents that modulate 
regulators of cell death represents an attractive approach to 
improve treatment response.
In GC-resistant ALL, the mechanisms underlying defective 
induction of mitochondrial apoptosis are still not understood. 
Increased expression of antiapoptotic myeloid cell leukemia 
sequence 1 (MCL-1) was a predominant feature of the gene expres-
sion signature of GC resistance (4). A bioinformatic screen of drug-
associated signatures identified rapamycin as a sensitizer to GC 
drugs in GC-resistant ALL. The GC-sensitizing effect of rapamycin 
was attributed to a decrease in MCL-1 levels, which was proposed 
to decrease the threshold to apoptotic stimuli by GC drugs (5).
Based on these considerations, we sought to evaluate the poten-
tial of the small molecule obatoclax (GX15-070) for combination 
therapy in refractory childhood ALL. This agent was proposed to 
act as a BCL-2 family antagonist and to disrupt the interaction 
between MCL-1 and its proapoptotic counterparts at cytotoxic 
concentrations (6, 7). Obatoclax was shown to trigger apoptosis 
at concentrations that resulted in disruption of Bak from MCL-1 
and cytochrome c release. However, obatoclax was also cytotoxic 
in cells that are deficient for the apoptosis effectors BAX and BAK, 
and lower concentrations of compound were sufficient to inhibit 
clonogenic growth of AML cells, suggesting the existence of addi-
tional target mechanisms (8). A recommended phase II dose has 
been established for adult patients with hematologic malignancies 
with an acceptable toxicity profile (9, 10), which constitutes the 
basis for further evaluation of obatoclax in pediatric trials.
In the context of defective apoptosis, an alternative cell death 
pathway has been identified that is dependent on macroau-
tophagy (11, 12), a major form of autophagy, in which parts of 
the cytoplasm and intracellular organelles are sequestered within 
characteristic double-membraned or multi-membraned autopha-
gic vacuoles (hereafter referred to as autophagy) (13). Autophagy 
is usually triggered to respond to increased metabolic require-
ments at times of cellular stress. Selected antiapoptotic BCL-2 
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family members can engage in cross-talk between the apoptotic 
and autophagic pathways, as they were show to associate with the 
autophagy regulator beclin-1 (11, 14, 15). When caspase-depen-
dent apoptosis was blocked, a cell death mechanism that required 
autophagy was mediated via the receptor-interacting protein 1 
(RIP-1) (12). RIP-1 is a central kinase that is associated with death 
receptor–induced signalling complexes to modulate the switch 
between survival and death under stress conditions (16). Under 
defective apoptotic conditions, RIP-1 kinase activity was shown 
to mediate an alternative cell death pathway that may represent 
a form of programmed necrosis, also called necroptosis (17, 18). 
Kinase activity of RIP-1 was shown to be dispensable for induc-
tion of cell survival signalling via NF-kB activation or death recep-
tor–mediated apoptosis (17, 19).
Here we show that a subcytotoxic concentration of obatoclax 
effectively restored the response to dexamethasone in GC-resistant 
ALL by triggering a nonapoptotic cell death pathway. Subcytotoxic 
concentrations of obatoclax induced disruption of beclin-1 from 
MCL-1 and the combination of dexamethasone with obatoclax 
was associated with inhibition of mammalian target of rapamycin 
(mTOR) activity, providing a possible mechanism for autophagy 
induction. Obatoclax also conferred clinically relevant broad che-
mosensitization in multidrug-resistant primary cells from VHR-
ALL patients. We provide genetic and pharmacologic evidence to 
show that sensitization to dexamethasone occurs via autophagy-
dependent necroptotic cell death, while sensitization to other cyto-
toxic agents was dependent on apoptosis. In a xenograft model, 
using GC-resistant cells from refractory ALL patients, combina-
tion treatment with dexamethasone and obatoclax reduced leu-
kemia progression significantly. Collectively, our data provide a 
strong rationale for a rapid clinical translation of this approach.
???????
Obatoclax resensitizes GC-resistant ALL to dexamethasone. Because 
MCL-1 has been proposed to act as a central modulator of steroid 
resistance in ALL (4, 5), we first compared the effects of 2 small 
molecules with different selectivity toward MCL-1, ABT-737, 
and obatoclax in GC-resistant ALL cell lines. ABT-737 is a small 
molecule BH3 mimetic with selectivity for BCL-2 and BCL-XL 
(20). Resistance to ABT-737 has been attributed to its inabil-
ity to target MCL-1 (21–23). While both compounds displayed 
strong cytotoxicity across a panel of ALL cell lines (Supplemental 
Table 1; supplemental material available online with this article; 
doi:10.1172/JCI39987DS1), subcytotoxic doses of obatoclax but 
not ABT-737 resensitized GC-resistant cell lines to dexamethasone 
(Figure 1A and Supplemental Figure 1). We confirmed single-agent 
activity for obatoclax in VHR-ALL cells (Supplemental Table 2). 
Low-dose obatoclax restored sensitivity to dexamethasone in 
cells from all 7 poor-prednisone-responder (PPR) VHR-ALL 
patients tested (Figure 1B and Supplemental Figure 2). In con-
trast, no effect on steroid sensitivity using low doses of ABT-737 
or obatoclax was evident in steroid-sensitive cells (Figure 1A). 
Unexpectedly, the pan-caspase inhibitor zVAD.fmk did not inter-
fere with the steroid-sensitizing effect of obatoclax in GC-resis-
tant cells (Figure 2A), whereas zVAD.fmk blocked the cytotoxic 
effect of dexamethasone with or without obatoclax in GC-sensi-
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tive cells and in control experiments when cell death was induced 
by staurosporine (STS). Using clonogenic assays, we confirmed 
that obatoclax was equally effective in ALL cells that are devoid 
of caspase-9 or BAX and BAK, when compared with parental cell 
lines (Figure 2B and Supplemental Figure 3). Furthermore, obato-
clax-mediated GC sensitization resulted in neither the restoration 
of mitochondrial membrane depolarization (Figure 2C) nor an 
increase in cytochrome c release when compared with the effect 
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of dexamethasone in GC-sensitive cells (Figure 2D). In line with 
these findings, caspase-9 was not activated and caspase-3 was 
only marginally activated in steroid-resistant cells treated with 
the combination of obatoclax and dexamethasone (Supplemental 
Figure 4). Collectively, our results indicate that the combination 
of obatoclax and dexamethasone triggers a cell death mechanism 
that is independent of the apoptotic function of caspases in ste-
roid-resistant leukemia.
Induction of autophagy is essential for steroid sensitization in ALL cells. 
Because an autophagy-dependent cell death pathway has been 
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described in cell line models in which apoptosis is prevented (11, 24), 
we evaluated next whether autophagy was required for GC sensitiza-
tion by obatoclax. Indeed, autophagosome formation was evident in 
GC-resistant cells after 4 hours of exposure to low-dose obatoclax 
in combination with dexamethasone, which correlated with genera-
tion of endogenous LC3-II (Figure 3, A–C). Because rapamycin is 
known to be an inducer of autophagy (25), we asked whether the 
GC-sensitizing effect reported recently for rapamycin (5) could also 
be dependent on autophagy. As we expected, steroid sensitization by 
rapamycin was associated with hyperautophagic features (Figure 3, 
A and B). Obatoclax or rapamycin alone only marginally induced 
autophagosome formation and generation of LC3-II (Figure 3, A–C). 
Preincubation with the autophagy inhibitor 3-methyladenine (3-MA) 
abolished autophagosome formation, generation of LC3-II, and GC 
resensitization by obatoclax and rapamycin (Figure 3, B–D). Both 
bafilomycin, a late-stage inhibitor of autophagolysosome formation 
(25), and downregulation of the essential autophagy genes beclin-1 
(BECN1) and ATG-7 (ATG7) by RNA interference blocked GC-resen-
sitization by obatoclax and rapamycin (Figure 3, D–G). These results 
were confirmed in an independent cell line (Supplemental Figure 5). 
Clonogenic assays demonstrate that both addition of 3-MA and 
downregulation of beclin-1 prevented the cytotoxic effect of low-
dose obatoclax combined with dexamethasone, since clonogenic 
growth was comparable to that in untreated controls (Figure 3, 
F and G). In GC-sensitive ALL cells, inhibition of autophagy by 3-MA 
only marginally restored GC resistance, despite small amounts of 
detectable LC3 lipidation (Supplemental Figure 6). These findings 
implicate autophagy as part of a common mechanism for GC resen-
sitization by obatoclax and rapamycin.
To determine whether obatoclax triggers the autophagy path-
way as a general response to blockade of mitochondrial apoptosis, 
we studied the drug’s effects on Bax–/–Bak–/– mouse embryo fibro-
blasts (MEFs), which exhibit resistance to a broad range of apop-
totic stimuli (26). Like rapamycin, obatoclax induced autophagy in 
Bax–/–Bak–/– MEFs (Figure 4, A–C), as reflected by autophagosome 
formation (Figure 4, A and B) and generation of LC3-II (Figure 4C). 
Obatoclax was cytotoxic to WT and Bax–/–Bak–/– MEFs, whereas 
ABT-737’s activity was restricted to WT MEFs (Figure 4D). The 
death response was blocked by 3-MA (Figure 4E) and downregu-
lation of beclin-1 or ATG-7 (Figure 4, F and G). Taken together, 
these results indicate that the cytotoxic effects of obatoclax and 
rapamycin derive from induction of autophagy when mitochon-
drial apoptosis is blocked.
Modulation of the GC response by obatoclax is associated with inhibition of 
mTOR. A key regulator of cell fate decisions, including regulation of 
autophagy, is the kinase mTOR (27). Inhibition of mTOR by rapa-
mycin resensitizes steroid-resistant ALL cells to dexamethasone (5), 
but the role of autophagy has not been investigated in this study. 
Since dexamethasone has been shown to inhibit mTOR in other cel-
lular systems (28), we investigated the effect of dexamethasone and 
obatoclax treatment on mTOR activity. Alone dexamethasone slight-
ly induced a decrease of S6 protein phosphorylation (Figure 5A). 
Treatment with obatoclax or rapamycin and dexamethasone resulted 
in a sharp decrease of the phosphorylation of the mTOR targets S6 
protein and 4EB-P1 (Figure 5A). Interestingly, rapamycin but not 
obatoclax, either alone or in combination with dexamethasone, 
induced dephosphorylation of AKT at Ser473 (Figure 5A). Combina-
tion of obatoclax or rapamycin and dexamethasone also resulted in 
????????
????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????
????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????
???????????????????????????????????? ?????????????????????????? ?????????????????????????????????? ???????????????????????????????????????????
??????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? ???????????????
?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????
???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????
????????????????
???? The Journal of Clinical Investigation   http://www.jci.org   Volume 120   Number 4   April 2010
dephosphorylation of S6 protein in primary ALL cells from steroid-
resistant high risk ALL patients (Figure 5B, left). In contrast, cells 
from steroid-sensitive patients did not show dephosphorylation 
of S6 protein after treatment with obatoclax and dexamethasone 
(Figure 5B, right). Our experiments suggest that in the context of GC 
resistance, exposure to dexamethasone could cooperate with expo-
sure to obatoclax to decrease mTOR activity. This finding will be 
exploited to develop correlative markers of biological response to in 
vivo treatment, for example, using phospho-flow cytometry to moni-
tor the phosphorylation status of S6 protein in leukemia cells.
Obatoclax disrupts a complex between beclin-1 and MCL-1. The anti-
apoptotic BCL-2 family member MCL-1 was proposed to act as 
a modulator of GC resistance (5). Because the autophagy regula-
tor beclin-1 was described to interact with antiapoptotic BCL-2 
family members, including MCL-1 (11, 14, 15), we next tested the 
effect of obatoclax on the interaction of beclin-1 with MCL-1. 
Subcytotoxic concentrations of obatoclax resulted in a markedly 
decreased detection of MCL-1 that coimmunoprecipitated with 
overexpressed, epitope-tagged beclin-1 in 293T cells (Figure 6A). 
We confirmed this result by performing coimmunoprecipita-
tion experiments of endogenously expressed proteins in ALL cells 
(Figure 6B). Again, in presence of subcytotoxic concentrations of 
obatoclax, less beclin-1 was shown to coimmunoprecipitate with 
MCL-1, and inversely, less MCL-1 was pulled down together with 
beclin-1. Obatoclax did not modify interactions between beclin-1 
and BCL-2. Interestingly, incubation with rapamycin or ABT-737 
did not affect the complex between beclin-1 and MCL-1. As expect-
ed from the reported MCL-1 interaction spectrum (29, 30), BIM 
was detectable by coimmunoprecipitation from steroid-resistant 
ALL cells, but binding of BIM to MCL-1 was not altered by treat-
ment with low-dose obatoclax. The BH3-only protein NOXA, 
which was shown to interact preferentially with MCL-1, did not 
bind to MCL-1 in this experimental setting (Figure 6B).
Since MCL-1 can be subjected to a high protein turnover (31), we eval-
uated the effect of combination treatment with obatoclax and dexa-
methasone on MCL-1 protein levels. In the presence of cycloheximide, 
MCL-1 levels rapidly decreased after 45 minutes of incubation, inde-
pendent of the presence of obatoclax and dexamethasone (Figure 6C). 
Absence of proapoptotic BIM induction by dexamethasone has been 
described in selected cases of steroid-resistant ALL (32). We did not 
detect any changes in BIM expression levels to correlate with the 
restored response to dexamethasone in combination with obatoclax 
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in GC-resistant ALL cells (Figure 6D). Interestingly, induction of BIM 
was not detectable consistently in steroid-sensitive cells (Figure 6D). 
While in RS4;11 cells, BIM was readily induced by dexamethasone, 
neither 697 cells nor primary ALL cell samples from steroid-resistant 
patients showed induction of this proapoptotic BH3-only protein 
after dexamethasone treatment (Figure 6D). In cells from steroid 
sensitive patients, a small increase in the BIM-L and BIM-S but not 
BIM-EL isoforms was detectable. These data indicate that steroid 
resensitization by obatoclax is not due to induction of BIM.
To obtain further insight into the role of MCL-1 for the mecha-
nism of action of obatoclax, we modulated MCL-1 expression 
using RNA interference. A reduction of MCL-1 protein levels 
resulted in partial resensitization to dexamethasone but, surpris-
ingly, prevented any additional chemosensitization by the combi-
nation with obatoclax (Supplemental Results and Supplemental 
Figure 7). Partial resensitization to dexamethasone was mediated 
via induction of apoptosis, which was blocked using the pan-cas-
pase inhibitor zVAD.fmk. Inhibition of autophagy with 3-MA did 
not affect the resensitization effect of MCL-1 knockdown to dexa-
methasone, even in presence of obatoclax. Instead, caspase-9 acti-
vation was detected, which correlated with a caspase-dependent 
decrease of beclin-1. Thus, it is possible that induction of apopto-
sis overrides induction of autophagy when MCL-1 is downregu-
lated, which limits the interpretation of these experiments. Taken 
together, our data indicate that disruption of the beclin–MCL-1 
interaction is part of the mechanism triggered by obatoclax and 
suggest an involvement of MCL-1 in the regulation of an autoph-
agy-dependent cell death pathway, in addition to its role as anti-
apoptotic regulator in leukemia cells.
Combination of obatoclax and dexamethasone triggers RIP-1 kinase–
dependent necroptosis in GC-resistant ALL. To better assess the nature 
of cell death occurring with obatoclax and dexamethasone, we pro-
ceeded with imaging by transmission electron microscopy. Indeed, 
autophagosome formation was evident after treatment with oba-
toclax and dexamethasone, which was completely inhibited by 
incubation with 3-MA (Figure 7, A and B). Cells displayed features 
consistent with a nonapoptotic cell death mechanism after expo-
sure to obatoclax and dexamethasone. Condensation of chromatin, 
a hallmark of classical apoptosis, was incomplete (Figure 7A, top 
row), which contrasts with the marked chromatin condensation 
after treatment with TRAIL, which induces death receptor–depen-
dent apoptosis in ALL cells (33). A characteristic feature of dead cells 
was the disintegration of the plasma membrane (Figure 7B), which 
is a hallmark of necroptosis (34). Increasing evidence suggests that 
a programmed necrotic cell death pathway can be triggered in the 
context of impaired apoptotic effectors, and this is dependent on 
RIP-1 kinase activity (12, 17). RIP-1 functions at the intersection of 
cell survival and cell death signalling (35, 36). Therefore, we test-
ed whether inhibition of RIP-1 with necrostatin-1 (nec-1; ref. 17) 
would interfere with steroid sensitization by obatoclax. Indeed, ste-
roid-resistant ALL cells treated with nec-1 were refractory to oba-
toclax-induced dexamethasone resensitization (Figure 7C). Nec-1 
also reduced the cytotoxic response to dexamethasone, alone or in 
combination with low-dose obatoclax in steroid-sensitive ALL cells 
(Figure 7C). Interestingly, nec-1 inhibited induction of BIM in ste-
roid-sensitive cells that showed BIM induction after dexamethasone 
(Supplemental Figure 8). Consistent with a central role for RIP-1 for 
the response to GC drugs, RIP-1–deficient ALL cells (37) were resis-
tant to obatoclax-mediated GC resensitization (Figure 7D).
The deubiquitinase cylindromatosis (turban tumor syndrome) 
(CYLD) is a direct regulator of RIP-1 kinase activity (38). Knocking 
down CYLD expression showed that CYLD is required for RIP-1–
dependent cell death induction by combination of dexamethasone 
and obatoclax (Figure 7E). Our results are consistent with the cur-
rent model, which proposes that the deubiquinated form of RIP-1 
is mediating cell death signals (35). An important finding is that 
induction of autophagy could be detected early, within 4 hours 
of treatment, and that generation of LC3-II was neither inhibited 
in RIP-1–deficient ALL cells (Figure 7F) nor in nec-1–treated ALL 
cells (Figure 7G). Taken together, these results demonstrate that 
the combination of obatoclax and dexamethasone triggers a non-
apoptotic cell death pathway, which shares the central features of 
necroptosis, including the characteristic morphology of cell death 
shown by electron microscopy, and a strict dependence on RIP-1 
kinase activity and RIP-1 deubiquitinase CYLD. Moreover, our 
data indicate that the autophagic process is triggered upstream of 
RIP-1 and does not occur as a consequence of necroptosis.
Obatoclax is a broad chemosensitizer in multidrug-resistant primary ALL 
cells, but activation of autophagy-dependent cell death is specific to the com-
bination with dexamethasone. To validate our results in primary cells, 
we tested pretreatment samples from PPR patients with precursor 
B cell ALL, who were further characterized by the molecular persis-
tence of leukemic cells under intensified conventional multiagent 
chemotherapeutic treatment and predicted to have a very high risk 
of relapse based on their poor in vivo response to chemotherapy 
(Supplemental Table 2). Indeed, low-dose obatoclax resensitized 
GC-resistant ALL cells to dexamethasone in mesenchymal stroma 
cell (MSC) cocultures, which was completely abolished using 3-MA, 
implicating autophagy as an essential mechanism in primary 
refractory ALL cells also (Figure 8A). At this dosage, obatoclax alone 
induces less than 5% cell death. Importantly, 3-MA did not interfere 
with the cytotoxic effect of treatment with dexamethasone, alone or 
combined with obatoclax, on primary ALL cells from GC-sensitive 
patients (Figure 8A), indicating that autophagy was not required 
for the death response to GC drugs in GC-sensitive cells. Consistent 
with our results in ALL cell lines, nec-1 abolished the GC-sensitiz-
ing activity of combination treatment in steroid-resistant primary 
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VHR-ALL cells. In contrast, blocking caspases with zVAD.fmk did 
not inhibit steroid resensitization in primary GC-resistant ALL 
cells, while the response to dexamethasone was inhibited by zVAD.
fmk treatment in cells from steroid-sensitive ALL patients.
Current treatment protocols include a steroid window followed 
by multidrug chemotherapy, including cytotoxic agents such as 
daunorubicin, vincristine, and cytarabine. Low-dose obatoclax 
resensitized primary refractory ALL cells to all 3 drugs, while the 
sensitivity of cells from sensitive patients was not increased fur-
ther. Interestingly, 3-MA did not restore resistance to these cyto-
toxic agents, indicating that induction of autophagy after treat-
ment with obatoclax is specific for GC resensitization (Figure 8B). 
In contrast, blocking caspases using zVAD.fmk completely inhib-
ited the resensitizing effect of low-dose obatoclax in combinations 
with daunorubicin, vincristine, and cytarabine, both in cells from 
very high risk and from standard risk patients. These results sup-
port the notion that autophagy-dependent necroptosis is specifi-
cally triggered with GCs in a GC-resistant context. Moreover, oba-
toclax could serve as a chemosensitizer for established multidrug 
regimens for ALL treatment, given its broad potential to restore 
the apoptotic response with non-GC antileukemic drugs.
Combination of obatoclax and dexamethasone is effective in a leukemia 
xenograft model, using cells from refractory ALL patients. To test the in 
vivo efficacy of obatoclax in GC resensitization, we transplanted 
primary ALL cells from 2 VHR-PPR patients into NOD/SCID/
IL2r?null (NSG) mice (39). When 1% human leukemic cells were 
detected in mouse peripheral blood, we treated mouse cohorts 
with vehicle, obatoclax (5 mg/kg/d), dexamethasone (5 ?g/kg/d), 
or both for 3 weeks. In vehicle-treated animals, progression to leu-
kemia (>10% peripheral blasts) was observed in a median time of 11 
weeks for animals xenografted with cells from patient VHR-02 and 
1 week for animals xenografted with cells from patient VHR-01. All 
mice xenografted with cells from patient VHR-02 and treated with 
single-agent dexamethasone or obatoclax had to be sacrificed due 
to leukemia progression, while only 2 out of 8 animals treated with 
the combination of obatoclax and dexamethasone progressed to 
leukemia over the 50-week observation period. A significant delay 
in leukemia progression was achieved by combination treatment 
with dexamethasone and obatoclax when cells from VHR-01 were 
used (P < 0.02 for combination treatment versus vehicle or single 
agent treatment). This patient showed the recurrent translocation 
t(17;19)(q22;p13), which is virtually always associated with early 
relapse (40) (Figure 8C). This result suggests that GC sensitization 
of VHR-PPR ALL cells can be achieved in vivo, providing a strong 
rationale to explore the therapeutic potential of combined dexa-
methasone and obatoclax clinically.
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Here we describe a pharmacological approach that we believe to 
be new to specifically bypass the apoptotic blockade to chemo-
therapy in multidrug-resistant ALL. Subcytotoxic concentrations 
of the BCL-2 antagonist obatoclax restored the response to dexa-
methasone by inducing a nonapoptotic cell death pathway. The 
activation of autophagy-dependent cell death in cells that are 
resistant to the apoptotic stimuli by dexamethasone is reminis-
cent of observations that were reported using experimental sys-
tems with defined genetic defects of key regulators of the intrinsic 
and extrinsic apoptotic response. In Bax–/–Bak–/– MEFs and BCL-2– 
overexpressing MEFs, cell death triggered by etoposide or STS was 
dependent on autophagy genes beclin-1 and ATG-5 (11). As also 
reported by others (6, 8), obatoclax was cytotoxic for Bax–/–Bak–/– 
cell lines, which we demonstrate to be critically dependent on the 
autophagy pathway. Similarly, genetic or pharmacologic inter-
ference with caspase 8 or death receptor signalling can result in 
autophagy-dependent cell death with necroptotic features (12, 18, 
41). In lymphoid cells, this may constitute an alternative mecha-
nism to control abnormal cellular proliferation in the absence of a 
normal apoptotic response. In activated T cells from mice with cas-
pase-8 or FADD deficiency, autophagic signalling was required to 
induce RIP-1–dependent necroptotic cell death (41). We here show 
that this mechanism of cell death can be activated in GC-resistant 
leukemia to restore the response to dexamethasone.
Autophagy has been recognized as an important regulatory 
mechanism of cell fate decisions. While it is clear that autophagy 
can have a protective function at times of cellular stress, the contri-
bution of autophagy to the execution of programmed cell death is 
a subject of controversy (13). Our data demonstrate that autopha-
gic signalling is an integral part of the cell death mechanism when 
the response to dexamethasone is restored with obatoclax or rapa-
mycin. Both inhibitors that interfere early (3-MA) or late (bafilo-
mycin) with the autophagic process and knockdown of genes that 
are essential for autophagy, BECN1 and ATG7, prevented resensiti-
zation to dexamethasone completely. Combination of dexametha-
sone and obatoclax inhibited clonogenic growth of GC-resistant 
ALL cells, and electron microscopy imaging unequivocally showed 
rapid induction of necrotic cell death with autophagic features. 
There is clear evidence that in cancer, autophagy is not necessarily 
a protective feature. For example, BECN1 was shown to act as a 
haploinsufficient tumor suppressor gene (42, 43), with increased 
frequency of spontaneous neoplasia, including lymphomas in 
beclin-1–haploinsufficient mice. The genes that are essential for 
the autophagic machinery are highly conserved and required in 
several autophagy-dependent cellular processes (44). Several stud-
ies link autophagy genes to programmed cell death. In the central 
nervous system for example, ATG7 deficiency protected neurons 
from caspase-dependent and caspase-independent cell death 
after hypoxic/ischemic brain injury (45). In human glioblastoma, 
knockdown of the autophagy genes ATG1 or ATG5 prevented 
the cytotoxic effect of cannabinoids, which induce autophagy-
dependent cell death via an mTORC1-dependent pathway (46). 
Autophagy was also shown to regulate programmed cell death 
during development. The steroid hormone ecdysone triggered 
autophagy-dependent cell death during morphogenesis of sali-
vary glands from the larval stage to the adult stage in Drosophila. 
This cell death pathway was independent of caspase activity (47), 
providing compelling evidence for the modulation of an autopha-
gic cell death pathway via steroid hormone signalling in normal 
development. Similarly, autophagy is required for programmed 
cell death in the midgut during Drosophila metamorphosis, which 
provides additional evidence for specific regulation of cell death by 
autophagy, even in presence of an intact apoptotic machinery (48). 
Combination treatment of obatoclax with GC drugs but not with 
other cytotoxic agents induced autophagy-dependent cell death in 
resistant ALL. This raises the question of whether autophagy is also 
required for the effect of dexamethasone in GC-sensitive ALL. A 
recent report described increased autophagy after dexamethasone 
treatment in GC-sensitive ALL cell lines, but cell death was associ-
ated with apoptotic features and knockdown of beclin-1 resulted 
only in partial rescue of this effect (49). We also observed a partial 
reduction of dexamethasone cytotoxicity using 3-MA (Supplemen-
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tal Figure 6) or nec-1 (Figure 7C) in a subset of GC-sensitive cell 
lines. We could, however, not detect an effect of 3-MA in primary 
ALL cells, in which caspase-dependent cell death prevailed. Our 
results identify autophagy as an early and limiting step to steroid 
sensitization by obatoclax in GC-resistant cells and underscore the 
importance of understanding the cellular context when designing 
strategies to target autophagy for cancer treatment.
There is clear evidence for hyperactivation of AKT (50) and 
mTOR (5) in GC-resistant ALL. Because mTOR is implicated in 
the control of autophagy in different settings (27), hyperactive 
AKT-mTOR signalling could prevent induction of autophagy in 
resistant disease. We hypothesized that GC-resistant ALL cells 
could therefore be primed for mTOR-controled autophagy. Con-
sistent with this idea, we found that induction of autophagic cell 
death by the combination of dexamethasone and obatoclax result-
ed in marked reduction in phosphorylation of the mTOR target 
S6 protein in resistant cells. The mechanisms by which obatoclax 
or rapamycin potentiate the effect of dexamethasone on mTOR 
appear to be different. Indeed combination of dexamethasone 
with rapamycin, but not with obatoclax, resulted in a marked 
decrease in phosphorylation of AKT on Ser473, consistent with 
recent finding showing that mTOR can also act upstream of AKT 
(51). Modulation of mTOR target phosphorylation was only seen 
when obatoclax was combined with dexamethasone, but not with 
other cytotoxic agents, suggesting that dexamethasone exposure 
contributes to inhibition of mTOR. Indeed, exposure to dexa-
methasone was reported to be associated with repression of mTOR 
signalling in myoblast cell lines and lymphoid cells (28, 52). The 
importance of mTOR for the control of autophagy is also under-
scored by the results of a comprehensive screen using a chemical 
compound library in order to identify new pharmacologic induc-
ers of autophagy, in which proautophagic activity of candidate 
molecules was always associated with decreased phosphorylation 
of mTOR targets (53). Extensive studies will be required to dissect 
the primary signalling events triggered by the combination of oba-
toclax and dexamethasone, as they may provide important clues 
about the mechanisms of drug resistance in ALL.
GC resistance does not appear to be associated with genetic or 
functional defects of the GC receptor in ALL (54, 55). Dexametha-
sone was proposed to induce apoptosis by increasing the levels of 
the BH3-only proapoptotic protein BIM, which were markedly 
reduced in selected cases of GC-resistant ALL (32). However, in most 
cases tested, we could not detect induction of BIM by dexametha-
sone in GC-sensitive cell lines and primary ALL cells. Furthermore, 
we did not detect increased levels of BIM, decreased MCL-1 pro-
tein levels, or increased MCL-1 protein turnover associated with 
steroid sensitization. Instead, we found, by immunoprecipitation 
of endogenous proteins, subcytoxic concentrations of obatoclax 
to result in the disruption of MCL-1 with beclin-1 in ALL cells. 
This suggests the possibility that MCL-1 could control induc-
tion of autophagy via beclin-1, as it was proposed for other BCL-2 
family members recently (14, 15). Interestingly, this effect was not 
seen in cells treated with rapamycin, again pointing out that the 
target mechanism of obatoclax is different. We recognize the fact 
that this effect could also result from indirect mechanisms on the 
protein complex, including MCL-1 and beclin-1. Furthermore, 
functional experiments modulating MCL-1 expression levels were 
not conclusive. Knockdown of MCL-1 resulted in moderate activa-
tion of apoptosis and partial sensitization to dexamethasone that 
was caspase dependent but prevented complete resensitization to 
dexamethasone by obatoclax and autophagic cell death. Activation 
of apoptosis is possibly overriding induction of autophagy in this 
context. In support of this hypothesis, we detected activation of 
caspase-9 after downregulation of MCL-1, with caspase-9–depen-
dent cleavage of beclin-1. This provides a possible mechanism to 
prevent autophagy induction when apoptosis is activated. Taken 
together, steroid modulation with low-dose obatoclax did not 
involve release of proapoptotic BCL-2 family proteins from MCL-1 
but triggered autophagy-dependent cell death by a mechanism 
that required the presence of MCL-1.
In this context, activation of autophagy is required to induce 
necroptosis, a form of programmed necrosis that has been 
described to occur when apoptosis is abortive due to caspase 
inhibition (16, 56). Execution of necroptosis is dependent on the 
RIP-1 kinase (17). Our data demonstrate that RIP-1 activity is 
absolutely required for steroid sensitization by obatoclax and by 
rapamycin. The cell death morphology that was documented by 
electron microscopy is consistent with the morphology reported 
for necroptosis (12, 56). Furthermore, the deubiquitinase cyl-
indromatosis (CYLD), which has been shown to regulate RIP-1 
(38), was functionally required for execution of necroptosis. This 
is consistent with experiments showing that RIP-1 kinase activ-
ity was required to trigger cell death and that ubiquitination of 
RIP-1 prevents cell death signalling (16, 19). RIP-1 and CYLD were 
included among the core genes that were identified in a functional 
siRNA screen for genes that were essential for necroptosis (18). To 
the best of our knowledge, we provide the first clinically relevant 
model with consistent validation in primary leukemia cells from 
patients with very high risk disease, in which the necroptotic path-
way can be exploited to restore response to therapy. As such, this 
will constitute a very relevant experimental model to study the 
mechanisms of necroptosis in depth. Our results clearly imply a 
direct link between the autophagic pathway and RIP-1–mediated 
signalling events leading to necroptosis. Autophagy is triggered 
early and independent of RIP-1 kinase activity, indicating that it 
acts upstream of necroptotic signals. A number of studies identify 
RIP functionally as part of a complex with proteins of the death 
receptor pathway, such as FADD and caspase-8 (35). Experiments 
using mouse models indicate that autophagy and necroptosis 
could be linked via recruitment of components of the death recep-
tor pathway to the membrane of autophagosomes (41). It is tempt-
ing to speculate that a similar mechanism is triggered in ALL cells 
upon costimulation with dexamethasone and obatoclax. Our find-
ings warrant extensive biochemical follow-up studies to under-
stand how RIP-1 is activated and how the autophagic machinery 
is connected to the necroptotic pathway.
Based on promising studies by others (32), we have established 
a leukemia xenograft model of de novo highly resistant ALL. The 
power of this approach resides in the possibility to select cases 
from relevant patient groups, starting from cryopreserved left-
over diagnostic samples, from one of the largest cooperative trials 
for the treatment of childhood ALL. By focusing on cases with 
VHR-ALL by MRD, we also selected for patients that are most 
significantly resistant to prednisone in vivo, as defined by the 
reduction of leukemia cells in the peripheral blood after 1 week 
of prednisone monotherapy. Accordingly, ALL cells from these 
patients were completely resistant to dexamethasone and other 
chemotherapeutic agents in vitro. Low-dose obatoclax restored 
the response to dexamethasone, both in precursor B cell and T cell 
ALL cases. The durable remissions observed with 1 year follow-up, 
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using the leukemia xenograft model, are indicative of strong 
antileukemic activity. Furthermore, the broad chemosensitizing 
effect of low-dose obatoclax in combination with daunorubicin, 
vincristine, and cytarabine in multidrug-resistant primary ALL 
cells provides a strong basis for further evaluation of obatoclax in 
combination with a multidrug regimen. The xenograft approach 
will be essential to validate this approach for heavily pretreated 
relapse and refractory patients. Our observation that isolated 
clones can emerge in clonogenic assays after treatment of a cell 
line with obatoclax and dexamethasone indicates that resistance 
to this approach may occur. Our established xenograft system will 
enable us to screen a larger number of ALL cases to verify whether 
resistance to this approach has to be expected. The identification 
of resistant cases would provide a model to establish markers 
that correlate with response or resistance. Based on current data, 
dynamic changes of mTOR activity with treatment represent a 
good candidate marker. Such knowledge will serve to optimize 
patient selection for clinical trials.
Taken together, our data support a model in which the apop-
totic blockade in GC-resistant ALL cells can be overcome by acti-
vating an autophagy-dependent necroptotic cell death pathway. 
The characteristic necroptotic features by electron microscopy 
and the changes in the phosphorylation profile of S6 protein pro-
vide tools to assess the biological response to combination treat-
ment with obatoclax and dexamethasone in patients in refractory 
ALL. Given the acceptable toxicity profile of obatoclax in clini-
cal studies in adults with hematologic malignancies (9, 10), our 
study provides a compelling rationale for the evaluation of this 
new pharmacological strategy for the treatment of children with 
refractory and relapsed ALL.
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Cell culture, reagents, and standard procedures. CEM-C7-14 and CEM-C1-15 
cells (referred to CEM-C7 and CEM-C1 in the text) were provided by E.B. 
Thompson (University of Texas Medical Branch, Galveston, Texas), human 
hTERT-immortalized primary bone marrow MSCs (57) were provided by 
D. Campana (St Jude Children’s Research Hospital, Memphis, Tennessee), 
caspase-9–deficient and retransfected Jurkat cells (58) as well as Bax/Bak-
deficient Jurkat cells (59) were provided by K. Schulze-Osthoff (Univer-
sity of Tübingen, Germany), and parental and Bax/Bak-deficient MEFs 
(26) were provided by J.-C. Martinou (University of Geneva, Switzerland). 
Rip1–/– cells were provided by B. Seed (Harvard Medical School, Boston, 
Massachusetts). Obatoclax was provided by J. Viallet and G. Shore (Gemin 
X, Malvern, Pennsylvania) and ABT-737 was provided by S. Elmore and S. 
Rosenberg (Abbott Laboratories, Chicago, Illinois).
Detailed procedures are described in Supplemental Methods. For RNA 
silencing experiments, 30 nM beclin-1 (sc-29797, Santa Cruz Biotechnology 
Inc.) was used. pEGFP-LC3 was provided by M. Jäättelä (Danish Cancer Soci-
ety, Copenhagen) and the FLAG-tagged beclin-1 construct by B. Levine (Uni-
versity of Texas Southwestern Medical School, Dallas). All constructs were 
transfected by nucleofection (Amaxa) using solution V and Amaxa program 
T-016 for CEM-C1, A-024 for CEM-C7 cells, and U-020 for MEFs. Transfec-
tion efficiency was controlled using the pEGFP plasmid (Clontech).
Patient samples. ALL cells were recovered from cryopreserved anonymized 
samples from patients who were enrolled in the ongoing ALL-BFM 2000 
protocol and had given informed consent in accordance with the Decla-
ration of Helsinki. Approval was obtained from the Institutional Review 
Board (IRB) of the Medical School Hannover and the local IRB for all par-
ticipating centers in the trial ALL-BFM 2000. This approval extends to the 
use of leftover diagnostic material for add-on research projects, including 
those addressing basic biological questions.
In vitro drug response. In vitro drug response curves in cell lines were 
established with the MTT assay and were normalized to vehicle con-
trol. Primary patient samples were cocultured on hTERT-immortalized 
human MSCs, and drug response curves were analyzed with flow cytom-
etry using propidium iodide.
Xenograft model. Xenograft experiments were approved by the veterinary 
office of the Canton of Zurich. In brief, primary ALL cells were recovered 
from cryopreserved samples and transplanted intrafemorally to NSG mice. 
Leukemia progression was monitored by flow cytometry with human 
CD45 and CD19 antibodies (AbD Serotec). ALL cells recovered from 
spleens of NSG mice after the first xenotransplantation were used for in 
vivo therapeutic trials. Randomized cohorts were treated with vehicle intra-
muscularly (i.m.): 3 mg/kg/d obatoclax i.m., 5 mg/g/d dexamethasone i.p., 
or the combination of dexamethasone i.p. and obatoclax i.m. for 5 days per 
week for 3 consecutive weeks.
Statistics. All experiments were performed 4 times, unless stated otherwise 
in the figure legends. Data are represented as mean ± SD. For in vitro experi-
ments, Student’s t test (2-tailed) was used on triplicates. P values of less than 
0.05 were considered significant. Event-free survival (EFS) was defined as 
the time from the start of treatment until 10% of human leukemia cells were 
detectable in the mouse peripheral blood and was assessed by Kaplan-Meier 
analysis. Survival curves were analyzed with the log-rank test (GraphPad 
prism). P values of less than 0.05 were considered significant.
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Supplementary results 
 
 
We performed cell viability and clonogenic assays to assess the effect of MCL-1 knock-down by RNA 
interference in GC-resistant ALL cells. Reduction of MCL-1 expression levels resulted in a partial 
increase in dexamethasone sensitivity of GC-resistant ALL cells. This was reversed by zVAD.fmk but 
not with 3-MA (Figure S7A), as assessed using 7AAD stainings by flow cytometry (upper panel) and in 
clonogenic assays (lower panel). Moreover, MCL-1 knock-down suppressed the marked GC-
sensitization effect by obatoclax that was observed in cells transfected with scrambled siRNA. In 
addition, reduction of MCL-1 levels resulted in activation of caspase-9 and in induction of 
mitochondrial membrane depolarization in cells treated with dexamethasone and obatoclax (Figure 
S7B and C), confirming that the partial GC-sensitization effect occurs by activation of apoptosis. As 
reported recently, apoptosis can suppress autophagy by enhancing caspase-mediated cleavage of 
beclin-1 (27). Indeed, exposure to dexamethasone and obatoclax resulted in a decrease of beclin-1 
levels after knockdown of MCL-1 (Figure S7D). The decrease in beclin-1 levels did not occur in cells 
with intact MCL-1 levels and was prevented by zVAD.fmk or in cells devoid of caspase-9. Taken 
together, our results show that MCL-1 is involved in preventing apoptosis induction in GC-resistant 
ALL cells, and that in absence of MCL-1, dexamethasone and obatoclax trigger mitochondrial 
apoptosis, which overrides the autophagy-dependent pathway. 
 
Supplementary methods 
Reagents  
Dexamethasone was purchased from Mepha Pharma, rapamycin from Calbiochem, and 3-
MA from Sigma. Obatoclax was provided by GEMIN X, ABT-737 by Abbott Laboratories, and 
rabbit antibodies were from Cell Signaling Technology (anti-Beclin-1, 1:1000 and anti-Bcl-XL, 
1:1000), Sigma (anti-actin, 1:3000 and anti-Mcl-1, 1:3000), ProSci (anti-APG7, 1:1000) and 
Abgent (anti-APG5L, 1:1000). Mouse-anti-LC3 (1:1000) was purchased from Axxora. FITC-
labelled anti-human CD45, PE-labelled anti-human CD19 and Alexa 647-labelled anti-mouse 
CD45 antibodies were from Serotec. 
Cell culture  
The ALL cell lines, CEM-C1 and -C7, 697 (ATCC #CRL-7433), MOLT-4 (ATCC #CRL-1582), 
Jurkat (ATCC #TIB-152) and REH (DSMZ, ACC22) were maintained in RPMI 1640 medium 
containing 10% heat-inactivated fetal bovine serum, 2 mM L-glutamine, and 100 IU/mL 
penicillin/streptomycin (Invitrogen). The RS4;11 (ATCC # CRL-1873) cell line was maintained 
in alpha MEM medium containing 10% heat-inactivated fetal bovine serum and 100 IU/mL 
penicillin/streptomycin (Invitrogen). Human mesenchymal stroma cells (MSC) were 
maintained in RPMI 1640 medium containing 10% heat-inactivated fetal bovine serum, 2 mM 
L-glutamine, 100 IU/mL penicillin/streptomycin and 50µM hydrocortisol (Sigma). Wild-type 
primary mouse embryonic fibroblasts and those deficient for BAX and BAK were maintained 
in DMEM containing 10% heat-inactivated fetal bovine serum, 2 mM L-glutamine, and 100 
IU/mL penicillin/streptomycin. For all compounds, the effect of treatment at low dose was 
used to normalize values for the calculation of survival curves. 
Immunoprecipitations and western analysis 
For immunoprecipitation experiments, treated cells were lysed in CHAPS-buffer (20 mM Tris-
Cl, pH 7.5, 137 mM NaCl, 2 mM EDTA, 10% glycerol and 2% CHAPS). Lysates were 
incubated with anti-MCL-1 (Stressgen), anti-Beclin-1 (Santa Cruz) combined with protein-G 
sepharose (Sigma). Washed beads were processed for western blotting. 
For Western blotting, whole-cell extracts were prepared from 1 x 106 cells using 
radioimmunoprecipitation assay (RIPA) buffer (50 mM Tris-Cl, pH 6.8, 100 mM NaCl, 1% 
Triton-X-100, 0.1% SDS) supplemented with complete mini protease inhibitor cocktail (Roche 
Applied Sciences) and 1 mM sodium orthovanadate (Sigma) for 20 minutes on ice. After 
SDS-PAGE, proteins were blotted onto nitrocellulose membranes. Membranes were blocked 
in 5% non-fat dry milk and incubated with primary antibodies in 3% bovine serum albumin 
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(Sigma). Horseradish peroxidase-labeled goat anti-rabbit or anti-mouse antibodies were used 
for signal detection with chemiluminescence substrate (Pierce) and direct scanning 
(Fujicolor).  
Fluorescence microscopy 
ALL cells and MEFs were transfected with the full-length rat pEGFP-LC3 as described above 
ALL cells were directly co-cultured with MSCs on coverslips for 24h and treated with DMSO, 
1 μM DEX, 100 nM obatoclax, or in combination, in the presence or absence of 3-MA 
(Sigma, 200 μM) for 4 hours. The cells were fixed with methanol for 20 min, washed three 
times with PBS, mounted with Vectashield on glass slides, and analyzed using a Zeiss 
META confocal microscope. Mouse embryonic fibroblasts were attached to coverslips for 24 
h after transfection and treated with obatoclax or rapamycin for 4 h and then fixed with PFA 
4% for 20 min. Nuclei were stained with DAPI in PBS for 10 min. The number of cells with 
punctate staining per 100 GFP-LC3 transfected cells was determined in two independent 
experiments. Counting was performed in six random fields, each representing 100 GFP-
positive cells and expressed as the mean ± SD.  
Transmission electron microscopy 
Jurkat cells were treated either with vehicle, dexamethasone and obatoclax (for 72h), TRAIL 
(for 24h) or with NaAzide (3% for 15min). Cells were harvested, washed with PBS 1X and 
fixed over night at 4°C in 3% glutaraldehyde in PBS. Cells were then washed and the pellet 
post-fixed for 1 h at RT with 2% osmium tetroxide and embedded into 2.5% agar in 50 mM 
sodium cacodylate buffer (pH 7.3), cooled down over night at 4°C and dehydrated in an 
ethanol series. The samples were diluted with EPON in increasing concentration and 
embedded in fresh EPON in capsules or flat silicone rubber moulds in the oven at 60°C for at 
least 12h. The samples were then analyzed using a CM 100 transmission electron 
microscope. 
Viability and Apoptosis Assays  
Cell culture was performed in 96-well plates with 2 x 104 ALL cells in cell suspension, or as 
co-culture of 105 primary ALL cells on 104 MSC, or with 105 MEF cells per well. Ten percent 
of the IC50 concentration of obatoclax or rapamycin was used for combination treatment with 
DEX, unless stated otherwise. Cell viability for ALL cell lines and MEF experiments was 
assessed using the MTT cell proliferation kit (Roche Applied Sciences) and, for primary ALL 
cells, by flow cytometry using 7AAD (BD biosciences). The minimal absorbance of control 
wells was OD 0.8. Caspase activation was detected by flow cytometry using the CaspGLOW 
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Red Active Caspase-3 Staining Kit (Alexis) according to the manufacturer's instructions, 
incubating1 µL specific substrate for caspase-3 (Red-DEVD-FMK) for 105 treated cells.  
Ratiometric Measurement of Mitochondrial Membrane Potential 
 
The mitochondrial membrane potential was assessed using the JC-1 mitochondrial 
membrane sensor (Invitrogen) according to the manufacturer’s instructions.  
 
 
Xenograft model 
106 primary ALL cells were recovered on dry ice in small portions from cryopreserved 
presentation samples, washed in PBS, and transplanted intrafemorally into Nod/LtSzScid 
IL2γnull mice. Xenografted ALL cells were recovered from the spleen and bone marrow, 
yielding more than 96% human CD45 and C19 positive cells per harvest as verified by flow 
cytometry, and were cryopreserved for cell culture experiments. 
For in vivo treatment, ALL cells recovered from a first xenotransplantation in NSG mice with 
cells from a precursor B-ALL patient with poor prednisone response were injected 
intrafemorally into cohorts of NSG mice (106 cells per animal). Leukemia progression was 
assessed by flow cytometry of the mouse peripheral blood using anti-mouse and human 
CD45 and CD19 antibodies. When 1% human cells were detectable in the peripheral blood, 
animals were randomized into 4 treatment groups and treated with either vehicle 
intramuscularly (i.m.; n=11 for patient 4 and n=6 for patient 2), 3 mg/kg/day obatoclax i.m. 
(n=8 for patient 4 and n=6 for patient 2), 5 μg/g/day DEX intraperitoneally (i.p; n=10 for 
patient 4 and n=6 for patient 2), or the combination of DEX i.p. and obatoclax i.m. (n=10 for 
patient 4 and n=6 for patient 2). Animals were treated 5 days per week for three consecutive 
weeks. Leukemia progression was monitored by flow cytometry.  
 
 Supplementary table S1: Cytotoxicity of obatoclax and ABT-737 in ALL cells. 
Indicated ALL cell lines were incubated with vehicle, 1 μM DEX, 10% IC50 dose of obatoclax, 
or the combination of DEX and obatoclax for 48h, and caspase activation was measured 
using flow cytometry. IC50 values obtained from MEF treatment are also presented. 
 
 
 
 
 
Cell line IC50 ABT-737, μM IC50 Obatoclax, μM 
 
CEM-C1  
 
0.242 ± 0.036 
 
0.980 ± 0.145 
Jurkat 0.103 ± 0.033 0.500 ± 0.037 
REH 1.564 ± 0.13 0.450 ± 0.097 
MOLT-4 0.146 ± 0.045 0.055 ± 0.009 
CEM-C7 0.058 ± 0.030 0.380 ± 0.079 
697 0.182 ± 0.018 0.122 ± 0.023 
RS4;11 0.014 ± 0.005 0.113 ± 0.011 
wt MEFs 1.234 ± 0.213 0.108 ± 0.025 
DKO MEFs N.D. 0.119 ± 0.022 
 
 
 
IC50 values were calculated using GraphPad prism software with triplicate values from MTT 
assays. 
 
 
 
Supplementary Table 2. Patient characteristics  
 
Characteristic                                                                        patient no. 
 VHR-01 VHR-02 VHR-03 VHR-05 VHR-06 VHR-07 HR-01 HR-02 SR-01 SR-02 SR-03 
Age, y 14 13 17 16 17 12 9 11 11 12 4 
Subtype pc-B pc-B pc-B pc-B pc-B pc-B T T pc-B pc-B pc-B 
Pred.resp. poor poor poor good good poor poor poor good good good 
Blast, d0 6 80 33 13 16 529 207 75 18 447 11 
BM blast d8 1.8 5.7 2.5 0.024 0.164 4.3 127 179 0.017 0.07 0.042 
BM blast d0 82% 90% 73% 84% 80% 80% 92% 70% 85% 96% 82% 
MRD VHR VHR VHR VHR VHR VHR HR HR SR SR SR 
Oba IC50 (nM)  1284 1521 983 993 1174 1317 1238 1535 923 875 1024 
 








